

DRAGON PHARMACEUTICAL INC  
Form 10KSB  
April 02, 2007

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

**FORM 10-KSB**

**ANNUAL REPORT UNDER SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For The Fiscal Year Ended December 31, 2006

Commission File Number 0-27937

**DRAGON PHARMACEUTICAL INC.**

(Exact name of small business issuer)

Florida

(State of other jurisdiction of incorporation or  
organization)

65-0142474

(I.R.S. Employer Identification Number)

650 West Georgia Street, Suite 310

Vancouver, British Columbia V6B 4N9

(Address of Principal Executive Offices)

[www.dragonpharma.com](http://www.dragonpharma.com)

(Registrant's Internet Address)

(604) 669-8817

(Registrant's telephone number including area code)

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act: Common Stock, par value \$0.001

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B is not contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. [ ]

Our revenues for the year ended December 31, 2006 were \$54,865,805

State the aggregate market value of the voting and non-voting common equity held by non-affiliates, computed by reference to the price at which the common equity was sold, or the average bid and asked priced of such common equity, as of March 15, 2007 was \$21,378,521.

The number of shares outstanding of the issuer's common stock as of March 15, 2007, was 62,878,004.

Is the Company a shell Company Yes \_\_\_ No X

Documents incorporated by reference: None

Transitional Small Business Disclosure Format: Yes \_\_\_ No. X



**TABLE OF CONTENTS**

<b>PART I</b>		<b>3</b>
<b>ITEM 1.</b>	<b>DESCRIPTION OF BUSINESS</b>	<b>3</b>
<b>ITEM 2.</b>	<b>DESCRIPTION OF PROPERTY</b>	<b>3</b>
<b>ITEM 3.</b>	<b>LEGAL PROCEEDINGS</b>	<b>20</b>
<b>ITEM 4.</b>	<b>SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS</b>	<b>20</b>
<b>PART II</b>		<b>21</b>
<b>ITEM 5.</b>	<b>MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</b>	<b>21</b>
<b>ITEM 6.</b>	<b>MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION</b>	<b>21</b>
<b>ITEM 7.</b>	<b>FINANCIAL STATEMENTS</b>	<b>27</b>
<b>ITEM 8.</b>	<b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS AND FINANCIAL DISCLOSURE</b>	<b>62</b>
<b>ITEM 8A.</b>	<b>CONTROLS AND PROCEDURES</b>	<b>62</b>
<b>ITEM 8B.</b>	<b>OTHER INFORMATION</b>	<b>62</b>
<b>PART III</b>		<b>62</b>
<b>ITEM 9.</b>	<b>DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT</b>	<b>62</b>
<b>ITEM 10.</b>	<b>EXECUTIVE COMPENSATION</b>	<b>65</b>
<b>ITEM 11.</b>	<b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b>	<b>67</b>
<b>ITEM 12.</b>	<b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.</b>	<b>69</b>

<b>ITEM 13.</b>	<b>EXHIBITS</b>	<b>70</b>
<b>ITEM 14.</b>	<b>PRINCIPAL ACCOUNTING FEES AND SERVICES</b>	<b>73</b>

## PART I

### ITEM 1.

#### DESCRIPTION OF BUSINESS

*With the exception of historical facts stated herein, the following discussion may contain forward-looking statements regarding events and financial trends that may affect Dragon Pharmaceutical Inc.'s future operating results and financial position. Such statements are subject to risks and uncertainties that could cause Dragon Pharmaceutical Inc.'s actual results and financial position to differ materially from those anticipated in such forward-looking statements. Factors that could cause actual results to differ materially include, in addition to other factors identified in this report, that Dragon Pharmaceutical has incurred losses since its inception, has a substantial amount of liabilities, all of which factors are set forth in more detail in the sections entitled "Item 1. Business Risks Associated With Dragon Pharmaceutical" and "Item 6. Management's Discussion and Analysis or Plan of Operation" herein. Readers of this annual report are cautioned not to put undue reliance on "forward looking" statements that are, by their nature, uncertain as reliable indicators of future performance. Dragon Pharmaceutical Inc.'s disclaims any intent or obligation to publicly update these "forward looking" statements, whether as a result of new information, future events, or otherwise except as required by law.*

*As used in this annual report, the terms "we", "us", "our", "the Company" and "Dragon" shall mean Dragon Pharmaceutical Inc. and its subsidiaries unless otherwise indicated. Further, unless otherwise indicated, reference to dollars shall mean United States dollars.*

#### General

We are a diversified pharmaceutical company with three key business units consisting of a Chemical division for manufacturing bulk active pharmaceutical ingredient (API) and pharmaceutical intermediates, a Pharma division for manufacturing formulated generic drugs with a focus on Cephalosporin antibiotics and freeze-dry injectables, and a Biotech Division for manufacturing biologics, currently Erythropoietin or EPO.

Dragon currently has four production facilities in Datong, China, including three GMP production facilities certified by Chinese State Food and Drug Administration ("SFDA"): one pharmaceutical facility with a capacity of producing freeze-dry injectables, one biotech facility producing Erythropoietin injectables and one chemical facility producing

bulk Clavulanic Acid. The fourth facility produces bulk 7-ACA, an intermediate for Cephalosporin antibiotics by a fermentation process. 7-ACA is an intermediate and no GMP is required for the production facility. The Company now has 47 drugs approved by the Chinese SFDA of which the Pharma division products are sold only in the Chinese markets while products from the Chemical and Biotech divisions are sold in both Chinese and selected international markets.

As discussed below, the Company completed the acquisition of Oriental Wave Holding Ltd. ("Oriental Wave") on January 12, 2005 which transformed us from a single product company into a diversified pharmaceutical company with three key business units consisting of a Biotech Division for biotech products, a Chemical division for bulk pharmaceutical intermediate and API and a Pharma division for formulated generic drugs.

The Company's headquarters, located in Vancouver, accommodates corporate functions such as financial reporting, SEC compliance, corporate finance, investor relations, and regulatory affairs for international product approval. The Company also has a corporate office in Beijing, China to manage all the businesses in China including strategy formulation in the Chinese market, product development, production and sales and marketing management.

## Corporate History

The Company was originally formed on August 22, 1989, as First Geneva Investments, Inc. First Geneva Investments was formed for the purpose of evaluating and acquiring businesses. On August 17, 1998, the Company acquired Allwin Newtech Ltd., a British Virgin Islands corporation. Allwin Newtech Ltd. was formed on February 10, 1998, for the purpose of developing pharmaceutical products in China. Allwin Newtech owned certain technology used to enhance the efficiency of producing EPO. On September 21, 1998, First Geneva Investments changed its name to Dragon Pharmaceutical Inc.

On January 12, 2005, we completed the acquisition of Oriental Wave. Oriental Wave was principally engaged in the production and sale of pharmaceutical products. In connection with the acquisition of Oriental Wave, the Company issued 44,502,004 shares of common stock to the three prior owners of Oriental Wave. As a result, these three prior owners of Oriental Wave collectively own 70.78% of our outstanding shares. The acquisition of Oriental Wave allowed us to expand our range of products, leverage both companies' marketing networks in China and in international markets, and improve our ability to execute our combined business strategy.

Oriental Wave, was the sole shareholder of Shanxi Weiqida Pharmaceutical Ltd. ( Shanxi Weiqida ), a China based pharmaceutical company engaged in the production, marketing and sale of pharmaceutical intermediates, active pharmaceutical ingredients and generic formulation drugs.

Shanxi Weiqida Pharmaceutical Ltd was primarily formed and organized through the acquisition of assets from three Chinese companies. Two of these acquisitions were completed out of bankruptcy procedures of state-owned pharmaceutical companies.

Shanxi Weiqida was formed in January 2002 as a Chinese domestic company. At the time it was established, Shanxi Weiqida acquired, for no cost, from Shanxi Tongling Pharmaceutical Co., Ltd., or Shanxi Tongling, all drug production permits, and product licenses of Datong No. 2 Pharmaceutical Factory, or Datong No. 2 Pharmaceutical. The assets of Datong No. 2 Pharmaceutical were acquired by Shanxi Tongling in June 2001 out of bankruptcy for RMB 42.3 million, or approximately \$5.1 million. Shanxi Tongling was founded in 1994 by Mr. Han, our current Chief Executive Officer.

In April 2002 Shanxi Weiqida acquired from Shanxi Tongzhen Pharmaceutical Co. Ltd all of its product licenses and production permits in consideration for assuming approximately RMB 6.7 million, or approximately \$0.8 million, of bank debt upon the liquidation of Shanxi Tongzhen.

In June 2002, Shanxi Weiqida purchased the assets relating to a capsules and injectables production line, including certain equipment, inventory, receivables and product licenses and related production permits, from Aurobindo Tongling (Datong) Pharmaceutical Co., Ltd., or Aurobindo Tongling (Datong), for consideration of approximately RMB 33.75 million, or approximately \$4.1 million. At the time of the transaction, Mr. Han was also the Chairman of Aurobindo Tongling (Datong).



In September 2002, Shanxi Weiqida acquired out of bankruptcy all assets of Datong Pharmaceutical Factory, or Datong Pharmaceutical, a state-owned enterprise, including the land use rights of Datong Pharmaceutical. Pursuant to the acquisition agreement entered into with the Datong Economic Committee of the Datong Municipal Government, Shanxi Weiqida acquired the assets in consideration for assuming all liabilities related to the employees of Datong Pharmaceutical. The agreement requires Shanxi Weiqida to pay the former employees of Datong Pharmaceutical certain minimum wages and health care costs until the date of their re-employment, retirement or death, whichever occurs first. Shanxi Weiqida has arranged for the re-employment or retirement of approximately 85% of the Datong Pharmaceutical employees.

In February 2003, Shanxi Weiqida commenced construction of a Clavulanic acid manufacturing facility, which was completed in August 2003. Pilot production began in August 2003 and full-scale production began in January 2004. Construction of Shanxi Weiqida's 7-ACA workshop was completed in December 2003 and pilot production of 7-ACA commenced on July 1, 2004. In July 2005, the Company started to ramp up the production.

In August, 2005, the Company closed its Biotech production facility in Nanjing, China and started the relocation of the Biotech production facility to a site next to the Chemical Division campus in Datong, China. The Company received the GMP certification for this new facility from the Chinese SFDA on December 29, 2005 and production at this facility started during the first quarter of 2006.

Shanxi Weiqida's head office is located in a special economic region in China. According to the tax laws for foreign enterprises, Shanxi Weiqida was granted a two-year national income tax exemption beginning in the first year after it became profitable and a 50% national income tax reduction for the following three years. Shanxi Weiqida became profitable in 2003. According to the current tax policy, the applicable tax rate for Shanxi Weiqida are 15% for 2006 and 2007. Pursuant to the Chinese Corporate Income Tax Law approved on March 16, 2007, the applicable income tax rate for Shanxi Weiqida starting 2008 is 25%. In addition, pursuant to a new regulation, No. 7 enacted during 2006 by the Shanxi Provincial Government, Shanxi Weiqida is exempted from the 3% Provincial income tax from 2006 to 2012.

On June 29, 2006, the Company signed an agreement with an arm-length third party to sell part of the Pharma division, including all the formulation production facilities located in the Economic Development Zone in Datong, China, 258 drug approvals from the Chinese SFDA, 900 employees and the whole direct sales team to hospitals for the formulation business and related inventories, account receivables and account payables. The total selling price for the assets was \$13.32 million. The transaction was completed on July 1, 2006. In addition, the Company also signed a separate agreement, with an amendment on July 28, 2006, to deliver international registration documentation and services on a related product to this arm-length third party. This documentation and services agreement is valued at \$1.5 million and was completed in September, 2006. The amended Agreement expanded the scope and coverage which will allow the Company to provide additional international registration documentation and assistance to complete the registration in other market areas. The fees related to the expanded scope will be negotiated and determined in the future.

Subsequent to the sales of part of the Pharma division, Oriental Wave transferred the ownership of Shanxi Weiqida to Allwin Biotrade Inc., another wholly owned subsidiary of the Company.

## **Business Segments**

The Company operates three key business units consisting of a Chemical division for bulk pharmaceutical API and intermediate such as Clavulanic acid and 7-ACA, a Pharma division for formulated drugs with a focus of Cephalosporin antibiotics and freeze-dry injectables, and a Biotech division for biologics products, such as

Erythropoietin or EPO.

Chemical Division

The Chemical Division's facilities are located on Datong Gongnong Road, Datong City, Shanxi Province, China. The Chemical Division produces bulk pharmaceutical intermediates and API to sell to other pharmaceutical companies for further processing and formulation into finished products. The Chemical Division manages the production of Clavulanic acid and 7-ACA for both Chinese and international markets. The designed production capacity for Clavulanic acid and 7-ACA were 30 tons and 400 tons respectively. After the Company's investment in the process optimization and technology improvement, the current production capacity reaches 50 tons and 600 tons for Clavulanic Acid and 7-ACA respectively. The production for Clavulanic Acid was started in January 2004 and the production of 7-ACA was started in July 2004.

One of the key products in Chemical Division is Clavulanic acid, a drug that combines with antibiotics increase the effectiveness of the antibiotics. Another key product in the Chemical Division is 7-ACA, an intermediate for Cephalosporin antibiotics. The 600-ton production capacity of 7-ACA positions Dragon among the main producers in the world. The export of 7-ACA to India commenced in 2004 and the Company currently has a target to sell 50% of its 7-ACA production to the Indian market. The Chemical Division operates its business strategies to upgrade its technology in order to improve yields and lower production cost, to develop 7-ACA and Clavulanic acid downstream bulk products, and to apply for approvals in the United States and European Union to enter into European and North American markets.

Pharma Division

After taking into consideration the sale of part of the Pharma division on July 1, 2006, the Company owns 36 drug approvals from the SFDA for the Pharma division, mostly Cephalosporin powder for injection and API. With this more focused product combination, the Company is able to take advantage of being one of the significant producers of 7-ACA, an intermediate for Cephalosporin antibiotics. The Company uses qualified contract manufacturers to produce the Cephalosporin powder for injection and key sales agents and distributors to sell the formulation products in the Chinese market. The Company believes that it will be able to utilize excess production capacity of other formulation producers without having to commit huge capital expenditure in its own production facility.

In addition to the cephalosporin product lines, the Pharma division also offers freeze-dry injectable products. The Company has a freeze-dry injectable workshop, next to the EPO production facility, for the freeze-drying of temperature sensitive pharmaceutical products. Among these products is Levofloxacin, a product marketed by the Company whose production was outsourced to a third party contract manufacturer.

Biotech Division

The Biotech Division's facility was relocated to Datong, China from its original production site in Nanjing City, China at the end of December, 2005. The new EPO production site is adjacent to the campus of the Chemical division, which already includes the entire basic infrastructure such as power, steam, purified water supply and water treatment facilities. The relocation of the EPO production site to Datong will allow the Company to capitalize on the existing production infrastructure and the efficiency of unified operational management. In the new facility, the capacity for bulk EPO doubled to 120 grams and the capacity for sterile vialing tripled to 5 million vials. The sole product of the Biotech Division is Erythropoietin or EPO, an injectable that stimulates red blood cell development. Dragon's Biotech Division develops, manufactures and markets generic EPO in China and developing countries as the current core markets. Currently, Dragon's EPO is sold only in countries where there is no patent protection. In the past, Dragon was preparing to enter the European market with a new EPO product under development in Austria. However, in January 2006, the Company sold the development contract with the Austrian partner to a related party for \$1 million cash and assumption of all commitments under the contract.

## **Products**

The following table describes the top five products of the Company in terms of revenue contribution.

### **Chemical Division**

The Chemical Division currently produces Clavulanic acid and 7-ACA. Clavulanic acid is used together with antibiotics to make the antibiotics more effective and longer-lasting. 7-ACA is an intermediate which is converted into active pharmaceutical ingredients to produce Cephalosporin antibiotics.

***Clavulanic acid.*** Beta-lactam antibiotics, such as the penicillins and cephalosporins, act by disrupting the development of bacterial cells walls thus causing the disintegration of the bacteria. However, some bacteria have acquired the genes to produce enzymes which inactivate this mode of action - so called beta-lactamases and thus drastically reducing the efficacy of this class of antibiotics. Clavulanic acid acts to inhibit the effectiveness of bacterial beta-lactamases since they are much more inclined to bond to Clavulanic acid than to beta-lactam antibiotics. In this way, bacterial beta-lactamases miss their target and the antibiotic has free access to the bacterial wall which it affects.

The Company's Clavulanic acid technology and production process was licensed and transferred from Alpha Process Trust Reg., or Alpha Trust. With the commencement of the production of Clavulanic acid in January 2004, the Company became the first commercial scale producer in China. By being the first producer in China, the Company believes it has a competitive advantage over other manufacturers to fulfill demands for Clavulanic acid domestically as well as internationally.

**7-ACA.** 7-ACA is made from Cephalosporin C and is a key intermediate for synthesizing cephalosporin antibiotics, the  $\beta$ -lactam antibiotics family. Produced by the fermentation of a filamentous fungus (Cephalosporium acremonium now known as Acremonium chrysogenum), cephalosporin C in the fermentation broth is isolated from the biomass by filtration. The strongly hydrophilic Cephalosporin C is purified by laborious adsorption and ion exchange steps. Cephalosporin C can be a free acid or a salt (sodium, potassium or zinc). The conversion of Cephalosporin C to 7-ACA has two methods, chemical process, and enzymatic process. The Company adopts the chemical process in the conversion of Cephalosporin C.

## **Pharma Division**

Subsequent to the sale of part of the Pharma division on July 1, 2006, the Company owns 36 drug approvals from the SFDA in three presentation formats: 16 types of powders for injection, 15 types of sterilized bulk drugs and five types of freeze-dry injectables. The Company focuses on generic drugs especially Cephalosporin antibiotics. With this more focused product combination, the Company is able to extend its cost competitive advantage as being one of the important producers of 7-ACA in China to downstream formulation products.

## **Biotech Division**

The Company's primary product of the Biotech division is EPO, a glycoprotein that stimulates and regulates the rate of formation of red blood cells. In adult humans, EPO is produced by the kidneys and acts on precursor cells to stimulate cell proliferation and differentiation into mature red blood cells. Kidney disease and chemotherapy or radiation therapy for treating cancer may impair the body's ability to produce EPO and, in turn, reduce the level of red blood cells to less than one-half that of healthy humans. The shortage of red blood cells leads to insufficient delivery of oxygen throughout the body. The result is anemia, which symptoms include fatigue and weakness.

One of the treatments for anemia is to provide EPO protein. This treatment is administered through dialysis tubing or by injection approximately three times per week. EPO is most commonly administered to people with chronic renal failure, HIV patients being treated with anti-viral drugs, and cancer patients on chemo or radiation therapy. The treatment is less dangerous and generates fewer adverse side effects than alternative treatments that include blood transfusions and androgen therapy. However, side effects of EPO may include hypertension, headaches, shortness of breath, diarrhea, rapid heart rate and nausea.

While EPO has been tested to be effective in treating anemia, there are other drugs and treatments currently that exist or are in development that can treat anemia. These alternative drugs or treatments could be proven more effective, less expensive or preferable to customers than EPO. The inability of EPO to compare favorably to these alternative drugs could have an adverse affect on our business.

## **Sales and Marketing**

Currently, the Company sells its products from the Chemical and Biotech divisions in both Chinese and international markets while only selling its Pharma division products in the China. The table below sets forth the Company's sales by product segments:



During 2006 and 2005, sales to the Company's five largest customers accounted for approximately 58.5% and 52.7% of the Company's sales, respectively; while sales to the Company's largest customer accounted for approximately 26.3% and 19.1% of the Company's sales, respectively. The Company has historically made its sales through purchase orders and not through long-term contracts.

### **Sales Models**

The Company maintains different sales and distribution models for different products. For cephalosporin formulation drugs, the Company sells through its sales offices to regional wholesalers throughout China. For EPO, the Company sells through its representatives to hospitals. For API and pharmaceutical intermediates, the buyers are other pharmaceutical companies who use our products as raw material for further processing and formulation. The Company's sales department covers both Chinese and international markets.

### **Pricing Policy**

All formulation drugs from the Pharma division and EPO from the Biotech division are subject to retail price control imposed by the government administration authorities. The main objective of price control policy is to set an upper limit to the retail prices of pharmaceutical products in order to prevent excessive increases in the prices of pharmaceutical products. The Company's products from Chemical Division are market-priced products and therefore not subject to retail price control.



## Facilities

The Company has an office in Vancouver, Canada to provide certain corporate functions of the Company, such as Finance, Investor Relations and International Regulatory Affairs. The Company has two manufacturing facilities for the Chemical Division and one manufacturing facility for the Pharma Division (freeze-dry injectable) in Datong, China. The Company's biotech facility was originally located in Nanjing, China but was closed in August, 2005 and relocated to Datong, China.

The Company's Chemical, Biotech and Pharma Division facilities are all located in Datong City. This campus, with a total area of approximately 947,200 square feet, houses the Clavulanic acid production facility, power, boiler, steam and water facilities and 7-ACA production facility, EPO and freeze-dry production facility. The land use right for this facility expires in August 2053.

All manufacturing facilities of the Company that are required to be GMP certified, have been certified under current Chinese regulations. The Company's GMP certificate for the Clavulanic acid facility of the Chemical division will expire and is subject to recertification in January 2009. The Company was granted the GMP certificate for its biotech and freeze-dry injectable facilities on December 29, 2005. Such GMP certificate will expire and is subject to recertification in December 2010. The 7-ACA facility does not need to be GMP certified. All the facilities of the Company have been designed to meet potential production demands into the foreseeable future.

## Competition

### Chemical Division

**Clavulanic acid.** The world production of Clavulanic acid is dominated by manufacturers located in Europe. Among them, Lek Pharmaceutical and Chemical Company of Slovenia, SmithKline Beecham Pharmaceuticals of Britain, Deva Holding A.S. of Turkey, Amifarma S.L. of Spain and DSM of the Netherlands, are the leading manufacturers of Clavulanic acid.

In China, there are three other producers of bulk Clavulanic acid, namely, Zhangjiakou International Pharmaceutical, Shanghai Antibioticos and Zhuhai Lianbang Pharmaceutical. The Company is currently the market leader of such product in China.

**7-ACA.** Production of 7-ACA is concentrated among a few European and Chinese manufacturers. The Company will face significant competition from these companies. The Company's international competitors include Antibioticos, a subsidiary of the Fidia Group of Italy and Biochemie, a subsidiary of Novartis of Switzerland. In addition, there are four leading manufacturers in China: China Pharmaceutical, Shangdong Lukang Pharmaceutical, Fuzhou Pharmaceutical and Harbin Pharmaceutical. Among them, Fuzhou Pharmaceutical does not sell 7-ACA in the market as it further processes all the 7ACA it produced into downstream APIs. Harbin Pharmaceutical is a buyer of 7ACA in the market since its capacity cannot fulfill its own demand to make downstream formulation products. Therefore, we believe that there are only two other key manufacturers of 7-ACA in China directly competing with the Company.

**Pharma Division**

The world market for Cephalosporin antibiotics is highly competitive and producers in this market include some of the largest pharmaceutical companies, including Pfizer Inc., GlaxoSmithKline, Schering-Plough, Abbott Laboratories and Sandoz.

There are numerous pharmaceutical manufacturers of Cephalosporin antibiotics in China. The top four producers are Harbin Pharmaceutical Group Holding Co., Ltd., Shijiazhuang Pharmaceutical Group Co., Ltd., Shanghai Pharmaceutical Co., Ltd. and North China Pharmaceutical Co., Ltd. All these companies or their affiliates are publicly traded companies listed on the Shanghai Stock Exchange or Hong Kong stock exchange. All of these competitors are substantially larger than the Company and have a more diversified product portfolio. The current Chinese market size for cephalosporin injectables is estimated to be 4 billion units and is expected to increase 15% annually in the next 5 years. The Company's strategy is to take over market share of smaller regional players that can not compete effectively due to strengthened GMP and quality requirements.

### **Biotech Division**

We have estimated that the world market for EPO to be approximately \$13 billion in annual sales and believe the market is growing. The market is dominated by three firms: Amgen Inc. of Thousand Oaks, California; Ortho Pharmaceutical Corp., a subsidiary of Johnson & Johnson, Inc. of New Brunswick, New Jersey; and Kirin Brewery Company Limited of Japan. EPO is marketed by Amgen as "Epogen," by Johnson & Johnson as "Procrit/Epex" and by Kirin as "Espo." A fourth participant in the international EPO market is Roche Holding AG of Switzerland, which markets an EPO drug with a different heritage.

In addition to these international drug companies, we are competing with existing and potential Chinese producers such as Sunshine SS Pharma and NCPC Genetech Biotechnology.

In addition, current and potential competitors may make strategic acquisitions or establish cooperative relationships among themselves or with third parties that could increase their ability to reach customers in the Chinese market. Such existing and future competition could affect our ability to penetrate the Chinese market and generate sales. No assurances can be given that we will be able to compete successfully against current and future competitors, and any failure to do so would have a material adverse effect on our business.

### **Intellectual Property, Government Approvals and Regulations**

#### **Intellectual Property**

The Company, through its subsidiary, Shanxi Weiqida, has 9 registered trademarks and has applied for registration of another 15 trademarks in China. Currently, the Company has submitted an application for a patent on a production technique.

Since all of the Company's products are generic drugs, they are not protected by any intellectual property rights except for their trade names.

#### **Regulation of the Chinese Pharmaceutical Industry**

The modernization of regulations for the pharmaceutical industry is relatively new in China and the manner and extent to which this industry is regulated will continue to evolve. As a pharmaceutical company, Shanxi Weiqida is subject to the Pharmaceutical Administrative Law, which governs the licensing, manufacturing, marketing and distribution of pharmaceutical products in China. Additionally, Shanxi Weiqida is subject to varying degrees of regulation by governmental agencies in China.

***Principal supervisory authority in the industry.*** SFDA is the principal supervisory authority in the pharmaceutical industry in China. It was established in March 2003 on the basis of the former State Drug Administration of China, which was established in March 1998. The SFDA is responsible for the administrative and technological supervision of the research, production and trading of pharmaceutical products and the consolidated supervision of the safety management of food, health care and cosmetic products.

***Certificates, permits and licenses for pharmaceutical manufacturing and trading enterprises.*** A pharmaceutical production enterprise or pharmaceutical trading enterprise must apply for the relevant permit from the relevant regulatory department in China. The Industry and Commerce Administration Department will issue a "business license" only after the pharmaceutical regulatory department has considered the application and approved the issue of a "pharmaceutical production permit" or "pharmaceutical trading permit". Such permits are valid for a period of five years and application for renewal must be made six months prior to its expiry date. A new permit will be issued after reassessment, examination and approval by the relevant pharmaceutical regulatory department.

***Good Manufacturing Practices ("GMP").*** GMP is a set of standards in respect of quality management of the manufacturing of pharmaceutical products which is promoted by the World Health Organization ("WHO"). These are applicable to the entire pharmaceutical production process and the key working procedures for the production of raw materials which affect the quality of finished medicine products. Many countries have formulated their own requirements for GMP based on the GMP promoted by WHO. The Administration Center of Pharmaceutical Certification of the SFDA is responsible for pharmaceutical GMP certification in China. A GMP certificate is valid for a term of five years and application for renewal has to be submitted three months prior to its expiration date.

***Prescription medicines and over-the-counter medicines.*** Prescription medicines must be dispensed, purchased and taken with the prescription of practicing doctors or assistant doctors. Purchase of over-the-counter medicines do not require doctors' prescriptions and can be dispensed, purchased and taken by users. The SFDA is responsible for the selection, approval, publication, and revision of the over-the-counter medicine catalogue.

Wholesalers of prescription and over-the-counter medicines and retailers of prescription and over-the-counter type A medicines must hold a "pharmaceutical trading enterprise permit". Commercial entities may engage in the retail of over-the-counter type B medicines subject to the approval of the provincial pharmaceutical regulatory authorities or their delegated bureaus. Prescription medicines may be advertised only in medical journals and over-the-counter medicines may be advertised in the mass media.

***Import and export restriction.*** Imported pharmaceutical products are required to meet certain safety and quality standards set by the Chinese government. In addition, these products should have been approved for sale in the country or region where they are manufactured. If the products are not approved in the foreign countries, they can be imported only subject to the approval from the SFDA. The export of pharmaceutical products when there is shortage of supply in China may be restricted or prohibited.

***Price control.*** In July 2000, in order to enhance market competition of the pharmaceutical industry and to reduce medical expenses, the former State Development and Planning Commission of the PRC promulgated a new policy in respect of reforming the price control of pharmaceutical products in China. According to the policy, the price of pharmaceutical products is subject to the control of the price supervising bureau at state and provincial levels. The bureau generally classifies pharmaceutical products into two groups: (1) government-pricing pharmaceutical products; and (2) market-pricing pharmaceutical products.





Pharmaceutical products where prices are determined by National Development and Reform Commission of the PRC are limited to Category A pharmaceutical products listed in Medicine Catalogue of National Basic Medical Insurance and pharmaceutical products with monopolistic attributes (including anaesthetic medicines, certain type of psychiatric medicines, vaccines and contraceptive drugs). The price of Category B pharmaceutical products listed in the Medicine Catalogue of National Basic Medical Insurance are determined by the price supervising bureau at the provincial level according to the price determination policies adopted by the Central Government.

On November 21, 2000, the former State Development and Planning Commission of the PRC promulgated Notice Regarding Rules on Application for Approval for the Prices of Pharmaceutical Products set by the PRC Government, stating that:

(i)

for all pharmaceutical products first launched in China as listed in the price index of the State Development and Planning Commission of China, drug manufacturing enterprises are required to submit their price-setting applications to the price supervising bureau at the provincial level. The provincial price supervising bureau would then transfer such applications to the former State Development and Planning Commission of the PRC after review for further approval;

(ii)

for all new pharmaceutical products first launched in China as listed in the price index of the provincial government, drug manufacturing enterprises are required to submit their price-setting applications to price supervising bureau at the provincial level;

(iii)

for the patented pharmaceutical products, Categories 1 and 2 new pharmaceutical

products not listed in Medicine Catalogue of National Basic Medical Insurance, after trial production in China, drug manufacturing enterprises are required to submit their price-setting applications to the price supervising bureau at the provincial level for preliminary approval when they make applications for formal production. Then the provincial price supervising bureau would then transfer such applications to the former State Development and Planning Commission of the PRC to determine the price;

(iv)

for the patented pharmaceutical products, Categories 1 and 2 pharmaceutical products not listed in Medicine Catalogue of National Basic Medical Insurance, which are not required to be carried out trial production in China,

drug manufacturing enterprises are required to submit their price-setting applications to the price supervising bureau at the provincial level for approval after one year from obtaining of the production approval or the first import permit. Then the provincial price supervising bureau would then transfer such applications to the Economic Planning Commission of China for further approval; and

(v)

for all pharmaceutical products currently sold in the China market as listed in The Price Index of the Provincial and the State Development and Planning Commission of China, before new prices are set by the relevant price supervising authorities according to the market survey information, drug manufacturing enterprises can sell their products at the then prevailing price.

All the formulation drugs from the Pharma division and EPO from the Biotech division are subject to retail price control imposed by the government administration authorities. The main objective of price control policy is to set an upper limit to the retail prices of pharmaceutical products in order to prevent excessive increases in the prices of pharmaceutical products. The Company's products from the Chemical Division are subject to market price fluctuation and are not subject to retail price control. If manufacturing costs increase for products of the Company that are subject to price ceilings, and the retail price for those products is not adjusted upwards, the Company's profitability may be adversely affected.

**Reimbursement.** Only those drugs that appear on the provincial and municipal reimbursement lists are covered by the national medical insurance system, which may favor locally-manufactured products as they may be lower cost alternatives. The State Development Planning Commission of China has announced its intention to re-examine the pricing of drugs in China.

**Product liability.** Product liability claims may arise if harmful products are sold to members of the public or if there are any alleged harmful effects from the consumption of the products. Under current Chinese laws, manufacturers and vendors of defective products in China may incur civil and criminal liability for loss and injury caused by such products.

## **Research and Development**

Dragon's research and development activities mainly focus on the improvement of product quality and production technology. In order to fulfil those objectives, the research and development department utilizes both internal and external resources, such as cooperation with universities and other research laboratories. From time to time the Company, through its subsidiary, has established on-going collaborations on production techniques development with external research institutes such as universities and other research laboratories.

Total expenditures on research and development for the years ended December 31, 2006 and 2005 were \$85,562 and \$96,347, respectively.

## **Geographical Breakdown**

64% and 70% of the Company's revenues for the years ended December 31, 2006 and 2005, respectively, were derived from customers located in China. The Company had sales of \$14,451,791 in the Chemical Divisions to customers in India, representing 27.6% of the Company's revenues for the year ended December 31, 2006; while the Company had sales of \$6,593,391 and \$644,100 in the Chemical and Biotech divisions to customers in India, representing 13% of the Company's revenues for the year ended December 31, 2005. Substantially all of the Company's assets at December 31, 2006 and 2005 were located in China.

## **Suppliers**

The Company uses many different raw materials in the manufacturing process of its pharmaceutical products. The Company mainly sources its raw materials in China, but also purchases raw materials from some overseas markets.

The Company has not entered into any supply contracts with any of its suppliers which exceed twelve months. During 2006, the Company did not experience any significant difficulties in sourcing raw materials and the management of the Company does not anticipate that, if required, it will face any material difficulties in sourcing its

raw materials from alternative suppliers.

## **Customers**

For the Chemical division, our customers are pharmaceutical companies that purchase our API and pharmaceutical intermediate for further processing and formulation.

For the antibiotic formulation products, our customers are regional wholesalers at the provincial, municipal or county level. They will then sell the drugs to hospitals and clinics within their territories.

For EPO, our customers in China are hospitals with dialysis clinic. For the international markets, our customers are our licensees which purchase the products from us and then resell it to hospitals.

## **Employees**

As of December 31, 2006, the Company has 11 employees in North America and approximately 1,000 employees in China. Employees in China are union members under the Chinese law and there has been no labor disputes.

## **Business Risks Associated with Dragon Pharmaceutical**

An investment in our common stock involves a high degree of risks. Before you invest, you should carefully consider the risks described below. If any of the following risks occur, our financial condition or results of operations could be materially affected.

### **Certain Officers and Directors have significant control.**

Messrs. Han and Weng and Ms. Liu, who are officers and/or Directors of our Company own, in the aggregate, 70.78% of our issued and outstanding shares of common stock. As a result, these shareholders will be able to control certain corporate governance matters requiring shareholders' approval. Such matters may include the approval of significant corporate transactions requiring a majority vote without seeking other shareholders' approval. They will also have the ability to control other matters requiring shareholder approval including our election of directors that could result in the entrenchment of management.

### **Dragon has a negative working capital and we must restructure the short-term loans.**

As of December 31, 2006, the Company had current liabilities of \$33.95 million and current assets of \$17.73 million, including cash and cash equivalents of \$1.08 million and accounts receivables of \$4.25 million. The excess of current liabilities over current assets is mainly due to the fact that the Company finances its operations, development of its new EPO and freeze-dry injectable facilities, and increased production level at its Chemical Division through operating revenues, accounts payables and short-term loans. As a result, Dragon must, during the upcoming twelve months, negotiate with its banks to restructure or renew its notes. Assuming that Dragon is successful in renegotiating its notes and that vendors continue to work with Dragon as to their accounts payables, Dragon believes that it will be able to fund its operations from product sales for the near future. However, there is no assurance that the Company will be able to renegotiate and extend its loans. If our banks do not extend our loan or they are extended on unfavourable terms, the Company may be adversely affected.

**Dragon relies heavily on main clients.**

Sales to the Company's five largest customers accounted for approximately 58.54% and 52.74% of the Company's sales for the year ended December 31, 2006 and 2005, respectively; while sales to the Company's largest customer accounted for approximately 26.3% and 19.1%, respectively. Although we do not anticipate that there will be a material change in these customer relationships, a change in demand for these products due to world competition, market forces or other factors outside of the control of clients, could adversely affect our sales and net income.

**Dragon relies heavily on the sale of a few products.**

Dragon's top five products for 2006 were 7-ACA, Avelil and Clavulanate Potassium, Amoxicillin Clavulanate Potassium (5:1), Ceftriaxone for Injection, Amoxicillin Clavulanate Potassium (2:1), while the top five products for 2005 were 7-ACA, EPO, clavulanic acid, Mezlocillin, and Amoxicillin Sulbactam. The top five products sold by Dragon amounted to approximately \$45.45 million and \$27.37 million of its sales during 2006 and 2005, respectively, representing approximately 82.83% and 78.07% of Dragon's total sales for those periods. Although we do not anticipate that there will be a material change in demand for these products, a change in demand for these products due to world competition, market forces or other factors outside of its control, could adversely affect our sales and net income.

**Shanxi Weiqida is required to contribute a portion of its net income to Reserve Funds which may not be distributed.**

By law, Shanxi Weiqida is required to contribute at least 10% of its after tax net income (as determined in accordance with Chinese GAAP) into a reserve fund until the reserve is equal to 50% of Shanxi Weiqida's registered capital, a further percentage of its after tax net income, as determined by Shanxi Weiqida's Board of Directors, into a staff welfare fund, and into an enterprise expansion fund if determined by the Board of Directors. The reserve fund and enterprise expansion fund are recorded as part of stockholders' equity but are not available for distribution to shareholders other than in the case of liquidation, while the staff welfare fund is recorded as a liability, and is not available for distribution to shareholders. As a result of this requirement, the amount of net income available for distribution to shareholders will be limited.

**We intend to raise additional capital through the issuance of equity securities that will dilute the ownership of other shareholders.**

We intend to raise additional capital through the issuance of our equity securities to finance our growth and reduce short-term debt and other liabilities. No assurance can be given that we will be successful in our efforts. Further the

issuance of equity securities will reduce other shareholders' ownership in us.



**We may be subject to product liability claims in the future that could harm our business and reputation.**

Product liability claims may arise if harmful products are sold to members of the public or if there are any alleged harmful effects from the consumption of our products. Under current Chinese laws, manufacturers and vendors of defective products in China may incur liability for loss and injury caused by such products, including having their business licenses revoked and facing criminal liability. Consistent with industry practice in China, Shanxi Weiqida does not carry liability insurance coverage. Should any product liability claim be brought against us, there is no assurance that it would not have an adverse impact on our business, profitability or business reputation.

**We will be dependent upon the services of Mr. Han.**

Mr. Yanlin Han is our largest shareholder and serves as our CEO and Chairman of the Board. As a result, our operations will be dependent on Mr. Han who has been the driving force behind the Company. If something happens to Mr. Han, this could divert management's time and attention and adversely affect our ability to conduct the combined business effectively.

**Dragon relies heavily on the China market and changes in the market could harm our business.**

During 2006 and 2005, 64% and 70% of Dragon's sales, respectively, were derived from China. It is anticipated that Dragon's products in China will continue to represent a significant portion of sales in the near future. As a result of its reliance on the China market, the operating results and financial performance of Dragon could be affected by any adverse changes in economic, political and social conditions in China. For example, if legislative proposals for pharmaceutical product pricing, reimbursement levels, approval criteria or manufacturing requirements should be proposed and adopted, such new legislation or regulatory requirements may have a material adverse effect on our financial condition, results of operations or cash flows. In addition, we will be subject to varying degrees of regulation and licensing by governmental agencies in China. At this time, we are unaware of any China legislative proposals that could adversely affect our business. There can be no assurance that future regulatory, judicial and legislative changes will not have a material adverse effect on Dragon, that regulators or third parties will not raise material issues with regard to compliance or non-compliance with applicable laws or regulations or that any changes in applicable laws or regulations will not have a material adverse effect on Shanxi Weiqida or our operations.

**Certain products are subject to price controls and if the related manufacturing costs increase, our potential profits may be harmed.**

In July 2000, in an effort to enhance market competition in the pharmaceutical industry and to reduce medical expenses, the former State Development and Planning Commission of the People's Republic of China promulgated a new policy to reform the price control of pharmaceutical products in China. According to the policy, the price of pharmaceutical products and biotech products is subject to the control by government bureaus at state and provincial levels. In the event that the sale prices of our products are limited by government bureaus at the state and provincial levels, this may have an adverse effect on our net income, especially if our costs associated with those products increase. All formulation drugs from our Pharma division and EPO from our Biotech division are subject to retail price control imposed by the government administration authorities, which accounted for approximately 17% of 2006 sales and 22% of 2005 sales. If manufacturing costs increase for these products that are subject to price ceilings, and the retail price for those products is not adjusted upwards, our profitability will be adversely affected.

**Dragon is required to maintain compliance with GMP standards.**

All pharmaceutical manufacturers in China, including Shanxi Weiqida, a subsidiary of Dragon, are required to comply with certain Good Manufacturing Practice, or GMP, standards by certain time limits and, if not met, their pharmaceutical manufacturing enterprise permits will be revoked or they will not be renewed and accordingly production will have to be terminated. A GMP certificate is valid for five years from the issuance date of such certificate.

Shanxi Weiqida has been accredited with all GMP certificates it requires for its production facilities. Shanxi Weiqida's GMP certificate for the Clavulanic acid facility of the Chemical division will expire and is subject to recertification in January 2009, and the GMP certificate for the EPO and freeze-dry facility of the Biotech division will expire and is subject to recertification in December 2010. The standard of compliance required in connection with GMP certificates may change from time to time, which may give rise to substantial compliance burdens and increase Shanxi Weiqida's costs in the future. If the recertification of any required GMP-related status is not granted, the relevant operations of Shanxi Weiqida may have to be terminated which in turn would have an adverse impact on our profitability.

**Currency conversion and exchange control could adversely affect our operations and profitability.**

The sales and expenses of Shanxi Weiqida are substantially settled in Renminbi, or RMB, however, our financial statements are reported in U.S. dollars. Accordingly, our net income, the value of our assets and our ability to pay dividends, if any, in U.S. dollars may be adversely affected by negative changes in the exchange rate of RMB against the U.S. dollar or other currencies.

Major reforms have been introduced to the foreign exchange control system of China. In 1994, the previous dual exchange rate system for RMB was abolished and a unified floating exchange rate system, based largely on supply and demand, was introduced. Since December 1996, under the rules of International Monetary Fund, or IMF, China has provided a free exchange of current accounts, while capital accounts have been subject to foreign exchange control. Foreign exchange transactions under a capital account, including foreign currency-denominated borrowings from foreign banks and principal payments in respect of foreign currency-denominated obligations, continue to be subject to significant foreign exchange controls and require the approval of the State Administration of Foreign Exchange. However, the payment in and transfer of foreign exchange for current international transactions, such as the payment of dividends or other distributions to shareholders, is deemed a current account and therefore is not subject to Chinese government controls or restrictions. Although China's commitment to IMF is unlikely to change, limitations on foreign exchange could affect our ability to obtain foreign exchange for capital expenditures and we continue to be exposed to negative changes in exchange rates.

On July 22, 2005, the Chinese government decided to no longer peg the value of the Renminbi to the US dollar but rather to a basket of currencies of its largest trading partners. The result was an appreciation of the Renminbi of approximately 2% against the value of the US dollar (and a further 3.6% increase by the end of 2006). The effect of the revaluation was an increase in the assets, liabilities, revenues and expenses of the Company and a foreign currency gain included in comprehensive income.

The majority of the company's assets, liabilities, revenues and expenses are denominated in Renminbi, which was tied to the US Dollar until July 22, 2005 and is now tied to a basket of currencies of China's largest trading partners, is not a freely convertible currency. The appreciation of the Renminbi against the US dollar would result in an increase in the assets, liabilities, revenues and expenses of the Company and a foreign currency gain included in comprehensive income. Conversely, the devaluation of the Renminbi against the US Dollar would result in a decrease in the assets, liabilities, revenues and expenses of the Company and a foreign currency loss included in comprehensive income.

**Dragon does not have patent protection and is subject to substantial competition.**

Dragon competes in the generic drug segment of the pharmaceutical industry and has no patent protection for any of its products. Many pharmaceutical companies compete in the same market segment with similar products or products having comparable medicinal applications or therapeutic effects which may be used as direct substitutes for Dragon's products. Further, many of these competitors are larger and have greater resources and market presence than Dragon. Larger competitors may, as a result of economies of scale, be able to afford to sell competing products at lower prices than Dragon. This will have an adverse effect on Dragon's profitability. These competitors include Harbin Pharmaceutical Group Holding Co. Ltd, Shijiazhuang Pharmaceutical Group Co., Shanghai Pharmaceutical Co., Ltd. and North China Pharmaceutical Co., Ltd.. As a result of the lack of patent protection, competitors with potential substitutes could launch similar products in the market with their prices analogous with or lower than those manufactured and sold by Dragon. Further, the lack of patent protection could also attract an even greater number of competitors who believe they can develop products that are substantially similar to those of Dragon at a lower cost.

**Chinese economic planning could negatively impact the pharmaceutical market in which our products are sold.**

China has a long history of a planned economy and is still subject to plans formulated by the Central Chinese government. In recent years, the Chinese government has introduced economic reforms aimed at transforming the Chinese economy from a planned economy into a market economy with socialist characteristics. These economic reforms allow greater utilization of market forces in the allocation of resources and greater autonomy for enterprises in their operations. However, many rules and regulations implemented by the Chinese government are still at an early stage of development and further refinements and amendments are necessary to enable the economic system to develop into a more market oriented form. No assurance can be given that any change in economic conditions as a result of the economic reform and macroeconomic measures adopted by the Chinese government will have a positive impact on the Chinese economic development or its pharmaceutical sector, which is the market where our products are sold. At the same time, there can be no assurance that such measures will be consistent and effective or that we will benefit from or will be able to capitalize on all such reforms.



**ITEM 2.**

**DESCRIPTION OF PROPERTY**

Our corporate administrative office is located at Suite 310, 650 West Georgia Street, Vancouver, British Columbia, Canada covering 2,222 square feet for approximately CDN\$73,000 (\$60,000) per annum until March 31, 2011. From March 2006 to March 2007, the Company subleased its original corporate administrative office space at 1055 West Hastings, Suite 1900, Vancouver, British Columbia, Canada V6E 2E9. The Company anticipates recovering \$124,000 and \$41,000 during fiscal 2006 and 2007, respectively, under its sublease agreement.

Company's production facilities for all three divisions are all located in Datong city, China. This production campus, with a total area of approximately 947,200 square feet, houses the Clavulanic acid, 7-ACA, EPO and freeze-dry injectable production facilities with its own boiler, power, steam and water facilities. The land use right for this campus expires in August 2053.

**ITEM 3.**

**LEGAL PROCEEDINGS**

We are not currently involved in any litigation.

**ITEM 4.**

**SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

No matters were submitted for shareholders vote during the fourth quarter.



**PART II****ITEM 5.****MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS**

Our common stock began quotation on the OTC Bulletin Board on October 9, 1998 under the symbol "DRUG". In addition, our shares of common stock are listed on the Toronto Stock Exchange under the symbol "DDD" and are quoted on the Berlin-Bremen Exchange, the Frankfurt Exchange and the XETRA Exchange under the symbol "DRP". The OTC Bulletin Board represents our primary market. Our common stock being quoted and traded on the Berlin-Bremen Exchange, Frankfurt Exchange and XETRA Exchange are without the Company's prior knowledge. The following quotations reflect the high and low bids for our common stock on a quarterly basis for the past two fiscal years as quoted on the OTC Bulletin Board. These quotations are based on inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

<b><u>Quarter Ended</u></b>	<b><u>Common Stock</u></b>	
	<b><u>High</u></b>	<b><u>Low</u></b>
December 31, 2006	\$0.54	\$0.30
September 30, 2006	\$0.58	\$0.41
June 30, 2006	\$0.94	\$0.45
March 31, 2006	\$0.78	\$0.57
December 31, 2005	\$0.85	\$0.51
September 30, 2005	\$1.00	\$0.69
June 30, 2005	\$1.03	\$0.75
March 31, 2005	\$1.26	\$0.80

 **Holders**

As of March 15, 2007, there were 59 registered holders of our common stock. Many of the shares of common stock are held in street name, there may be additional beneficial holders of our common stock.

**Dividend Policy**



We have paid no dividends on our common stock since our inception and may not do so in the future. For the foreseeable future, we expect earnings, if any, will be retained to finance the growth of the Company.

**ITEM 6.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION**

*Except for statements of historical facts, this section contains forward-looking statements involving risks and uncertainties. You can identify these statements by forward-looking words including "believes," "considers," "intends," "expects," "may," "will," "should," "forecast," or "anticipates," or the negative equivalents of those words or comparable terminology, and by discussions of strategies that involve risks and uncertainties. Forward-looking statements are not guarantees of our future performance or results, and our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under "Risk Factors." This section should be read in conjunction with our consolidated financial statements.*

The following discusses the Company's financial condition and results of operations for the years ended December 31, 2006 and 2005 based upon the Company's consolidated financial statements which have been prepared in accordance with the United States generally accepted accounting principles. Due to the fact that Dragon's acquisition of Oriental Wave Holding Limited ( Oriental Wave ) on January 12, 2005 is deemed to be a reverse-take-over transaction, the following discussion reflects the Company's results of operations for the year ended December 31, 2005, including the results of Oriental Wave for the full year and the results of Dragon's biotech business for the period of January 12, 2005 to December 31, 2005. In addition, since the Company sold part of the Pharma division business on July 1, 2006, that part of the Pharma division business sold was reclassified as discontinued operations in the Company's results of operations for the years ended December 31, 2006 and 2005.

### **Results of Operations for the Fiscal Years Ended December 31, 2006 and 2005**

Sales for the year ended December 31, 2006 increased 57% to \$54.87 million from \$35.06 million for the same period in 2005. \$35.26 million or approximately 64% of the sales for the year ended December 31, 2006 were generated from the sales of products in the Chinese market, and the remaining \$19.61 million or approximately 36% were generated from the sales of products in the international markets (outside of China). 70% of the sales for the year ended December 31, 2005 were generated from the sale of products in the Chinese market while the remaining 30% of the sales were generated in the international market outside of China. In the year ended December 31, 2006, \$6.61 million or approximately 12% of the sales were from the Pharma Division, \$45.80 million or 83% of sales were from the Chemical Division, and \$2.46 million or 5% of sales were from the Biotech Division. For the same period in 2005, 11% of sales were from the Pharma Division, 78% of sales were from the Chemical Division, and 11% of sales were from the Biotech Division. The increase in sales for the year ended December 31, 2006 as compared to the prior year was primarily due to increase in sales from the Chemical and Pharma Division.

Cost of sales for the year ended December 31, 2006 was \$44.85 million compared to \$30.57 million for the same period of 2005. The cost of sales is attributed to the production costs of products. The increase in the cost of sales was mainly due to the increase in production and sales of products from the Chemical and Pharma Divisions. Gross profit and gross margin for the year ended December 31, 2006 were \$10.02 million and 18.25% compared to \$4.49 million and 12.80% for the same period of 2005. The increase in gross margin was mainly due to an improved margin of the Chemical Division as a result of an increase in production level and hence, better utilization of the production facilities.

#### *Divisional Revenues and Gross Margin Analysis*

The Company's businesses are organized under three business divisions: the Chemical Division, the Pharma Division and the Biotech Division.

Chemical Division

The Chemical Division's revenues for the year ended December 31, 2006 were \$45.80 million, representing a 68% increase from the revenues of \$27.33 million during the same period in 2005. The increase is due to the increase of sales from both the China market and international market.

The Chemical Division's gross margin for the year ended December 31, 2006 was 19.85% compared to 3.97% for the year ended December 31, 2005. The increase in gross margin reflected the lowering of per unit production cost as the production level continued to increase.

Pharma Division

The Pharma Division's revenues for the year ended December 31, 2006 were \$6.61 million, accounting for 12% of the total revenues of the Company. Comparatively, Pharma Division's revenues were \$3.90 million for the same period in 2005, contributing 11% of the total revenues of the Company. The 70% increase in revenues of the Pharma division during 2006 as compared to 2005 was mainly due to the increase in sales quantity as the Company has a more focused product and sales strategies.

The overall gross margin for the division for the year ended December 31, 2006 was -12.76% as compared to 15.90% for the same period of 2005. The decrease in the gross margins was due to a lowering of selling prices of the products.

Biotech Division

The Biotech Division's revenues for the year ended December 31, 2006 were \$2.46 million representing 5% of the Company's revenues for the year. Comparatively, Biotech Division's revenues were \$3.83 million for the same period in 2005, contributing 11% of the total revenues of the Company. The decrease was due to the Company having less international sales as the Company relocated its biotech production facility to the city of Datong during 2006. Such a new production facility may be required to be approved by regulatory bodies of certain international countries in which the Company intends to sell its products. Gross margin for the year ended December 31, 2006 was at 71.88% as compared to 72.57% for the same period of 2005. The gross margin was slightly lower because of the lowering percentage of contribution from international sales during 2006 which typically carries a higher margin than sales in the Chinese market and a slightly lower price in the Chinese market in 2006 than in 2005.

**Expenses.** Total operating expenses were \$9.06 million for the year ended December 31, 2006. The major category of operating expenses was general and administration expenses of \$5.75 million, selling expense of \$2.31 million, and depreciation and amortization expenses of \$1.00 million. Total operating expenses were \$8.12 million for the year ended December 31, 2005 with the major expenses being general and administration expenses of \$5.22 million, selling expense of \$2.00 million, and depreciation and amortization expenses of \$0.90 million. During the year ended December 31, 2006, the general and administration expenses included \$1.60 million for salaries, compensation and benefits, \$0.68 million for accounting and auditing, \$0.49 million for travel expenses, \$0.39 million for non-cash stock-based compensation, \$0.34 for consulting fees, and \$0.29 million for office and miscellaneous compared to \$1.79 million for salaries, compensation and benefits, \$0.34 million for accounting and auditing, and \$0.49 million for travel expenses, \$0.28 million for consulting fees, and \$0.41 million for office and miscellaneous for the same period in 2005.

The increase in operating expenses of \$0.94 million for the year ended December 31, 2006 as compared to the same period for the prior year reflects the increased overhead related to an increase in non-cash stock-based compensation expense, audit fees and consulting fees related to the compliance of Sarbanes-Oxley Act as well as selling expenses due to an increased in revenues especially for the Chemical Division.

***Other Income / Expense*** During the year ended December 31, 2006, the Company recognized a net other expense of \$1.74 million. This amount primarily consisted of \$3.24 million of interest expense (including \$ 1.67 million cash interest expense and \$1.57 million non-cash accreted interest expense on the long term payable), which was offset partly by a \$1 million gain on the sale of the European EPO cell line development and \$0.57 million government grant from the Chinese government. The other expense for the year ended December 31, 2005 was 0.66 million.

**Income from Discontinued Operations.** During the third quarter of 2006, the Company completed the sales of part of the Formulation business and the Registration Documentation Services to an unaffiliated party. As a result of the transactions, the Company recognized an after-tax gain of \$4.22 million from the disposal of assets and an after-tax income of \$0.92 million from the discontinued operations for the year ended December 31, 2006. Comparatively, the Company recognized an after-tax income of \$4.50 million from the discontinued operations for the year ended December 31, 2005.

**Net Income.** Dragon had a net income of \$4.62 million for the year ended December 31, 2006 compared to a net income of \$0.18 million for the same period in 2005,

**Comprehensive Income.** Dragon had foreign currency translation income of \$1.18 and \$0.75 million as other comprehensive income for the years ended December 31, 2006 and 2005, respectively. The foreign currency translation income results from translation of the financial statements expressed in RMB to United States Dollar.

On July 22, 2005, the Chinese government decided to no longer peg the value of the Renminbi to the US dollar but rather to a basket of currencies of its largest trading partners. The result was an appreciation of the Renminbi of approximately 2% against the value of the US dollar (and a further 3.6% increase by the end of 2006). The effect of the revaluation was an increase in the assets, liabilities, revenues and expenses of the Company and a foreign currency gain included in comprehensive income.

**Basic Net Income Per Share.** Dragon's net income per share has been computed by dividing the net income for the period by the weighted average number of shares outstanding during the same period. Net income per share for the year ended December 31, 2006 was \$0.07 per share and \$0.00 for the year ended December 31, 2005. The weighted average number of shares outstanding during year ended December 31, 2006 was 62,878,004 and was 62,273,862 shares during year ended December 31, 2005. The outstanding common stock options have no significant dilutive effect on the weighted average number of shares outstanding.

Dividends of the PRC subsidiary may only be distributed after allowance has been made for i) recovery of losses, if any; ii) appropriations to the reserve fund; iii) appropriations to the staff welfare fund; and iv) appropriations to an enterprise expansion fund if determined by the Board of Directors. Under current regulation, appropriations to the reserve fund should be at least 10% of the after tax net income determined in accordance with the PRC GAAP until the reserve is equal to 50% of PRC subsidiary's registered capital; appropriations to the staff welfare fund are at a percentage, as determined by the Board of Directors, of the after tax net income determined in accordance with the PRC GAAP; appropriations to the enterprise expansion fund are made at the discretion of the Board of Directors. The reserve fund and enterprise expansion fund are recorded as part of stockholders' equity but are not available for distribution to shareholders other than in liquidation; while the staff welfare fund is recorded as a liability and is not for distribution to shareholders. As at December 31, 2006, the Company's reserve fund is \$2.69 million, 11.14% of the Company's registered capital.

*Liquidity and Capital Resources*

As of December 31, 2006, Dragon had current liabilities of \$33.95 million and current assets of \$17.73 million, including cash and cash equivalents of \$1.08 million and accounts receivables of \$4.25 million. The working capital deficiency is mainly due to the fact that some long-term account payables and bank loans will become due within a year and therefore transferred from long-term liabilities to short-term liabilities.

The Company has developed and is implementing a plan to decrease its debt and increase its working capital which will allow the Company to continue operations.

To meet these objectives, the Company plans to seek additional equity through the conversion of some of its liabilities and expects to raise funds through private placements in order to support existing operations and expand the range and scope of its business. The Company has also significantly increased production levels to generate additional cash flow under contracted supply agreements. In addition, the Company intends to continue to renegotiate and extend loans, as required, when they become due, as has been done in the past. There is no assurance that such additional funds will be available for the Company on acceptable terms, if at all or that the Company will be able to negotiate and extend the loans. If adequate funds are not available or not available on acceptable terms or the Company is unable to negotiate or extend its loans, the Company may be required to scale back or abandon some activities. Management believes that actions presently taken provide the opportunity for the Company to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company's financial statements do not include any adjustments that might result from this uncertainty.

As of December 31, 2006, Dragon had current liabilities of \$33,953,660 as follows:

Accounts Payable		\$5,709,796
Other Payables and Accrued Expenses		\$15,337,446
Loans Payable-Short Term:		
RMB 20 million loan payable to a bank, interest rate of 6.138% per annum, collateralized by property and equipment of \$9,587,611, due January 2007	2,558,363	
RMB 4.35 million loan payable to a bank, interest rate of 7.905% per annum, guaranteed by an unrelated third party, due April 2007	556,444	
RMB 3.78 million loan payable to a bank, interest rate of 7.344% per annum, collateralized by property and equipment of \$1,075,470, due September 2007.	483,530	
RMB 2.9 million loan payable to a bank, interest rate of 7.344% per annum, collateralized by property and equipment of \$1,455,420, due September 2007.	370,963	
RMB 15 million loan payable to a bank, interest rate of 7.956% per annum, collateralized by property and equipment of \$2,773,565, due September 2007.	1,918,772	
RMB 52.3 million loan payable to a bank, interest rate of 7.956% per annum, collateralized by property and equipment of \$11,110,851, due December 2007	6,690,118	
RMB 1.7 million loan payable to a company, non-interest bearing and uncollateralized, due December 2007	220,855	
Loans Payable - Short Term Subtotal		\$12,799,045
Due to related companies		\$107,373



Total Current Liabilities

\$33,953,660

The accounts payable were incurred as part of the normal course of business of Dragon while other payables and accrued expenses were incurred as part of the investment in establishing the Chemical Division in 2004 and investment in the EPO workshop and Freeze-dry Injectable workshop during 2005.

As of December 31, 2006, Dragon had outstanding short-term loans (less than one year term) totaling \$12.80 million. Dragon believes that it will be successful in the renegotiating loans due based on the assumption that the Company has enhanced its ability to generate additional cash flow from its operation since the loans were originally entered into, even though there is no assurance of renewing the loans.

Long-term Liabilities:

At December 31, 2006, Dragon had long-term liabilities of \$11,085,359 as follows:

Long-term accounts payable	\$4,049,862
Loan Payable Long Term	\$7,035,497
Total Long-term Liabilities	\$11,085,359

As of December 31, 2006, Dragon had long-term loans payables (one to two years) totaling approximately \$7.04 million due December 2008, in addition to long-term accounts payable of \$4.51 million which will become due during 2008. The long-term accounts payable, which are non-interest bearing, have been discounted at 6.5% and are carried in the financial statements at \$4.05 million.

During the year ended December 31, 2006, Dragon financed its operations and increased production level at its Chemical Division through operating revenues, accounts payables and short-term loans. Dragon intends to seek additional funding through equity financing to improve its financial position, which may include conversion of certain receivables by certain vendors of Shanxi Weiqida into Dragon common stock.

Subsequent to December 31, 2006, the Company entered the following Loan agreements:

- A loan agreement with a bank for \$2,558,363 (RMB 20 million) bearing interest at a rate of 7.956% per annum, secured by property and equipment of \$9,587,611, and is due in January 2008.

- A loan agreement with a bank for \$3,197,953 (RMB 25 million) bearing interest at a rate of 6.732% per annum, secured by land and buildings of \$10,022,386, and is due in February 2008.

**ITEM 7.**

**FINANCIAL STATEMENTS**

The following Financial Statements pertaining to Dragon are filed as part of this annual report:

Report of Independent Accountants	28
Year-end Consolidated Balance Sheets	29
Year-end Consolidated Statements of Operations	30
Year-end Consolidated Statements of Stockholders' Equity	31
Year-end Consolidated Statements of Cash Flows	32
Notes to Consolidated Financial Statements	34

---

**DRAGON PHARMACEUTICAL INC.**  
**AND SUBSIDIARIES**  
**CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**  
**Expressed in US Dollars**

**CONTENTS**

PAGE	28	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
PAGE	29	CONSOLIDATED BALANCE SHEETS AS AT DECEMBER 31, 2006 AND DECEMBER 31, 2005
PAGE	30	CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005
PAGE	31	CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005
PAGE	32	CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005
PAGES	34-61	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2006 AND 2005

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and Shareholders of

**Dragon Pharmaceutical Inc.**

We have audited the accompanying consolidated balance sheets of **Dragon Pharmaceutical Inc.** as at December 31, 2006 and 2005 and the consolidated statements of operations and comprehensive income, stockholders' equity, and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform an audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Dragon Pharmaceutical Inc. as at December 31, 2006 and 2005 and the consolidated results of its operations and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

As discussed in Note 1 to the consolidated financial statements, the Company's recurring working capital deficiency raises substantial doubt about its ability to continue as a going concern. Management's plan in regard to these matters is described in *Note 1(A)*. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

As discussed in Note 1 to the Consolidated Financial Statements, effective January 1, 2006, the Company has adopted the provision of Statements of Financial Accounting Standards No. 123(R), *Share Based Payment* and No. 151, *Inventory Cost* an amendment of ARB No. 43, Chapter 4.

Vancouver, Canada

March 27, 2007

/s/ Ernst & Young LLP

Chartered Accountants

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS****AS AT DECEMBER 31, 2006 AND 2005****Expressed in US Dollars****(Basis of Presentation Note 1)**

<u>ASSETS</u>	Notes	December 31, 2006	December 31, 2005
<b>CURRENT ASSETS</b>			
Cash and cash equivalents	19	\$ 1,078,536	\$ 1,311,378
Restricted cash	10,19	-	3,327,829
Accounts receivable, net of allowances	2	4,252,470	4,352,236
Inventories, net	3	11,219,909	9,532,537
Prepaid expenses		1,183,442	1,199,941
Assets held for sale	7	-	8,270,429
Total Current Assets		17,734,357	27,994,350
<b>PROPERTY AND EQUIPMENT, NET</b>	4,9	62,681,205	61,153,955
<b>OTHER ASSETS</b>			
Intangible assets, net	6	2,578,858	2,984,994
Investments -cost		12,792	12,392
Goodwill		965,000	965,000
Total Other Assets		3,556,650	3,962,386
Assets held for sale	7	-	8,455,805
<b><u>TOTAL ASSETS</u></b>		\$ 83,972,212	\$ 101,566,496
<b><u>LIABILITIES AND STOCKHOLDERS EQUITY</u></b>			
<b>CURRENT LIABILITIES</b>			
Accounts payable		\$ 5,709,796	\$ 2,332,129
Other payables and accrued liabilities	8	15,337,446	13,637,203
Loans payable short-term	9	12,799,045	13,479,554
Notes payable	10	-	3,327,829
Due to related companies	11	107,373	61,993
Liabilities held for sale	7	-	8,464,387
Total Current Liabilities		33,953,660	41,303,095

**LONG-TERM LIABILITIES**

Long term accounts payable	12	4,049,862	12,216,832
Loans payable long-term	9	7,035,497	9,515,851
Liabilities held for sale	7	-	5,700,941
Total Long-Term Liabilities		11,085,359	27,433,624
<b>TOTAL LIABILITIES</b>		<b>45,039,019</b>	<b>68,736,719</b>

**COMMITMENTS AND CONTINGENCIES**

(Note 15)

**STOCKHOLDERS EQUITY**

Authorized: 200,000,000 common shares at  
par value of \$0.001 each

Issued and outstanding: 62,878,004

(December 31, 2005: 62,878,004) common  
shares

		62,878	62,878
Additional paid-in capital		33,411,788	24,317,830
Retained earnings		855,249	5,099,891
Reserves		2,693,426	2,628,008
Accumulated other comprehensive income		1,933,781	750,102
Due from stockholders		(23,929)	(28,932)
Total Stockholders Equity		38,933,193	32,829,777
<b><u>TOTAL LIABILITIES AND</u></b>		<b>\$</b>	<b>\$</b>
<b><u>STOCKHOLDERS EQUITY</u></b>		<b>83,972,212</b>	<b>101,566,496</b>

The accompanying notes are an integral part of these consolidated financial statements.



**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF OPERATIONS****AND COMPREHENSIVE INCOME****FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005****Expressed in US Dollars**

	Note	2006	2005
<b>SALES</b>	13	\$ 54,865,805	\$ 35,056,320
<b>COST OF SALES</b>		44,850,659	30,570,027
<b>GROSS PROFIT</b>		10,015,146	4,486,293
<b>OPERATING EXPENSES</b>			
Selling expense		2,307,786	1,996,407
General and administrative expenses		5,747,732	5,224,549
Depreciation and amortization		1,001,881	901,035
Total Operating Expenses		9,057,399	8,121,991
<b>INCOME (LOSS) FROM OPERATIONS</b>		957,747	(3,635,698)
<b>OTHER INCOME (EXPENSE)</b>			
Interest expense		(3,242,005)	(1,332,045)
Other income	14 (A) , (B)	1,703,806	52,974
Funds Released by Chinese Government Liquidator	14 ( C )	-	885,864
Other expense		(198,924)	(266,643)
Total other income (expenses)		(1,737,123)	(659,850)
<b>LOSS FROM OPERATION BEFORE TAXES</b>		(779,376)	(4,295,548)
<b>INCOME TAX RECOVERY (EXPENSE)</b>	17	175,976	(19,028)
<b>LOSS FROM CONTINUING OPERATIONS</b>		(603,400)	(4,314,576)
<b>INCOME FROM DISCONTINUED OPERATIONS</b>	7	5,137,917	4,497,146

<b>NET INCOME</b>	4,534,517	182,570
<b>OTHER COMPREHENSIVE INCOME</b>		
Foreign currency translation	1,183,679	750,102
<b>COMPREHENSIVE INCOME</b>	\$ 5,718,196	\$ 932,672
Earnings (Loss) per share - basic and diluted		
- from continuing operations	\$ (0.01)	\$ (0.07)
- from discontinued operations	\$ 0.08	\$ 0.07
- net income	\$ 0.07	\$ 0.00
Weighted average number of shares outstanding during the year - basic		
	62,878,004	62,273,862
- diluted	62,878,004	62,273,862

The accompanying notes are an integral part of these consolidated financial statements.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

	Common Stock		Additional	Retained	Reserves	Accumulated	Due from	Total
	Shares	Amount	Paid-In	Earnings		other	Stockholder	
			Capital			compre-		
						hensive		
						income		
Balance, December 31, 2004, adjusted for the effect of recapitalization of reverse acquisition (Note 5)	44,502,004	\$ 44,502	\$ 13,983,002	\$ -	\$ 7,562,432	\$ -	(52,149)	\$ 21,537,787
Reverse acquisition (Note 5)	18,376,000	18,376	7,919,370	-	-	-	-	7,937,746
Related party debt settled for equity (Note 18)	-	-	2,415,458	-	-	-	-	2,415,458
Notes receivable stockholders	-	-	-	-	-	-	23,217	23,217
Other comprehensive income								
- foreign currency translation	-	-	-	-	-	750,102	-	750,102
Transfer from reserves								
to retained earnings Note 16 (A)				5,204,022	(5,204,022)	-	-	-
to liabilities	-	-	-	-	(17,103)	-	-	(17,103)
Transfer from retained earnings	-	-	-	(286,701)	286,701	-	-	-

for reserves (Note  
16(A))

Net income for the  
year ended

December 31, 2005

- - - 182,570 - - - 182,570

**Balance,**

**December 31, 2005**

62,878,004 \$ 62,878 24,317,830 5,099,891 2,628,008 750,102 (28,932) 32,829,777

Notes receivable  
stockholders

- - - - - - 5,003 5,003

Other  
comprehensive  
income

- foreign currency  
translation

- - - - - 1,183,679 - 1,183,679

Stock compensation  
expense

- - 387,206 - - - 387,206

Transfer from  
reserves:

- to additional  
Paid-in Capital  
(Note 15 ( C) and  
16(A))

766,355 (766,355) -

Transfer from  
retained earnings to  
additional Paid-in  
Capital: (Note 15 ( C) and  
16 (A))

7,940,397 (7,940,397) -

-Transfer from  
retained earnings to  
reserves (Note 16  
(A)):

(838,762) 838,762 -

-Transfer from  
reserves to Staff  
welfare fund (Note  
16 (A)):

(6,989) (6,989)

Net income for the  
year

- - - 4,534,517 - - - 4,534,517

**Balance,**

**December 31, 2006**

62,878,004 \$ 62,878 \$ 33,411,788 \$ 855,249 \$ 2,693,426 \$ 1,933,781 \$ (23,929) \$ 38,933,193

The accompanying notes are an integral part of these consolidated financial statements.



**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF CASH FLOWS****FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005****Expressed in US Dollars**

	2006	2005
<b>CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES:</b>		
Loss from continuing operations	\$ (603,400)	(4,314,576)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:		
Depreciation and amortization	5,608,154	5,278,083
Stock compensation expense	387,206	-
Accreted interest on long term payable	1,567,000	144,741
Gain on disposal of cell line (Note 14(A))	(1,000,000)	-
Loss on disposition of assets	40,362	54,592
Write-off of acquired research and development (Note 5)	-	265,000
Funds Released by Chinese Government Liquidator (Note 14(C))	-	(745,828)
Changes in operating assets and liabilities, net of effect of reverse acquisition		
Accounts receivable	245,635	(2,360,707)
Inventories	(1,341,194)	1,156,689
Value added tax receivable	-	164,028
Prepaid expenses	53,993	(149,179)
Other receivables	-	(1,234,006)
Accounts payable	3,278,097	2,012,159
Other payables and accrued expenses	5,429,430	(4,861,759)
Cash Provided by (Used in) continuing operations	13,665,283	(2,122,761)
Cash Provided by (Used in) discontinued operations	(4,515,563)	12,917,270
Net Cash Provided By Operating Activities	9,149,720	10,794,509
<b>CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES:</b>		
Purchase of property and equipment	(5,742,776)	(11,945,688)
Purchase of intangible assets	(62,642)	-

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Cash and cash equivalents acquired in connection with reverse acquisition (Note 5)	-	2,103,481
Cash Used in continuing operations	(5,805,418)	(9,842,207)
Cash Provided by (Used in) discontinued operations	8,072,239	(210,363)
Net Cash Provided by (Used In) Investing Activities	2,266,821	(10,052,570)
<b>CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES:</b>		
Due from stockholder	5,058	47,501
Due to related parties	(171,071)	(3,994,813)
Repayment of long-term account payable	(8,577,228)	
Proceeds from non-interest bearing demand loan	563,776	
Proceeds from loans payable	17,694,915	3,575,670
Repayment of loans payable	(21,518,112)	-
Net Cash Provided by (Used In) Financing Activities	(12,002,662)	(371,642)
<b>EFFECT OF EXCHANGE RATE CHANGES ON CASH</b>	<b>353,278</b>	<b>30,656</b>
<b>NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>(232,842)</b>	<b>400,953</b>
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b>	<b>1,311,378</b>	<b>910,425</b>
<b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>	<b>\$ 1,078,536</b>	<b>1,311,378</b>
Cash paid during the period for interest expense	\$ 1,826,697	1,318,590
Cash paid during the period for income taxes	\$ 954,932	598,787

The accompanying notes are an integral part of these consolidated financial statements.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:**

The Company capitalized interest of \$127,176 and \$242,066 during 2006 and 2005, respectively.

The Company paid interest of \$1,826,697 and \$1,318,590 during the year ended December 31, 2006 and 2005, respectively, and paid income tax of \$954,932 and \$598,787 during the year ended December 31, 2006 and 2005, respectively.



The accompanying notes are an integral part of these consolidated financial statements.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 1**

**SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION**

**(A) Organization and Basis of Presentation**

The consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries: Oriental Wave Holding Limited ( Oriental Wave ) (incorporated in the British Virgin Islands), Shanxi Weiqida Pharmaceutical Co., Ltd. ( Shanxi Weiqida ) (incorporated in China), Beijing Weixang Bio-tech Co. Ltd.( Beijing Weixiang ) (incorporated in China), Allwin Newtech Ltd. (incorporated in the British Virgin Islands), Sanhe Kailong Bio-pharmaceutical Co., Ltd. (incorporated in China), Nanjing Huaxin Bio-pharmaceutical Co. Ltd. ( Huaxin ) (incorporated in China), Allwin Biotrade Inc. (incorporated in the British Virgin Islands) and Dragon Pharmaceuticals (Canada) Inc. (incorporated in Canada). All significant inter-company balances and transactions have been eliminated upon consolidation.

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has a working capital deficiency of \$16,219,303 as at December 31, 2006, however, the Company has developed and is implementing a plan to decrease its debt and increase its working capital which will allow the Company to continue operations as discussed below.

The Company plans to seek additional equity through the conversion of some of its liabilities and expects to raise funds through private placements in order to support existing operations and expand the range and scope of its business. The Company has also significantly increased production levels to generate additional cash flow under contracted supply agreements. In addition, the Company intends to continue to renegotiate and extend loans, as required, when they become due, as has been done in the past. There is no assurance that such additional funds will be available for the Company on acceptable terms, if at all or that the Company will be able to negotiate and extend the loans. If adequate funds are not available or not available on acceptable terms or the Company is unable to negotiate or extend its loans, the Company may be required to scale back or abandon some activities. Management believes that actions presently taken provide the opportunity for the Company to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time. These conditions raise substantial doubt about the

Company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty.

**(B) Use of Estimates**

In preparing consolidated financial statements in conformity with U.S. generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses for the reported period. Actual results could differ from those estimates.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**(C) Cash and Cash Equivalents**

The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

**(D) Accounts Receivable**

The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated risks by performing credit checks and actively pursuing past due accounts. An allowance for doubtful accounts is established and recorded based on management's assessment of the credit history with the customer and current relationships with them.

**(E) Investments**

The Company's investment in a private company represents less than 1% of the total equity outstanding of the private company outstanding as of December 31, 2006. The investment is carried at cost and written down to estimated fair market value when indications exist that this investment has other than temporarily declined in value. As of December 31, 2006, no impairment in the value of the investment has been recorded.

**(F) Inventories**

Inventories are stated at the lower of cost or replacement cost with respect to raw materials and the lower of cost and net realizable value with respect to finished goods and work-in-progress, cost being determined on a weighted average basis. The Company provides inventory allowances based on excessive spoilage and obsolete inventories determined principally by customer demand and product expiration dates.

In November 2004, the FASB issued SFAS No. 151, "Inventory Costs" an amendment of ARB No. 43, Chapter 4, which is the result of the FASB's project to reduce differences between U.S. and international accounting standards. SFAS No. 151 requires idle facility costs, abnormal freight, handling costs, and amounts of wasted materials (spoilage) be treated as current-period costs. Under this concept, if the costs associated with the actual level of spoilage or production defects are greater than the costs associated with the range of normal spoilage or defects, the difference would be charged to current-period expense, not included in inventory costs.

SFAS No. 151 was adopted by the Company beginning January 1 2006. The adoption of SFAS No. 151 did not have an impact on the Company's consolidated financial statements during the year ended December 31, 2006.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**(G) Property and Equipment**

Property and equipment is recorded at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis over the assets estimated useful lives, less an estimated residual value. The estimated useful lives are as follows:

Land use rights and buildings	50 Years
Plant and equipment	10 Years
Motor vehicles	8 Years
Furniture and office equipment	5 Years

Leasehold improvements are being amortized over the term of the lease (5-10 years).

Land use rights are recorded at cost, less accumulated amortization. The land use rights are amortized over the term of the relevant rights of 50 years from the date of acquisition.

Depreciable assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable based on projected undiscounted cash flows associated with the assets. A loss is recognized for the difference between the fair value and the carrying amount of the assets. Fair value is determined using a discounted cash flow analysis.

**(H) Fair Value of Financial Instruments**

The carrying amount of the Company's cash and cash equivalents, accounts receivable, investments, amounts due to related parties and short-term loans and other payables approximates their fair value. The fair value of long-term loans payables and long-term accounts payable are estimated using discounted cash flow analysis, based upon the Company's current borrowing rates, and approximate their carrying value.

**(I) Intangible Assets**

Intangible assets represent acquired customer base and production technology, licenses and permits for the production and sales of pharmaceutical products in China and are amortized on a straight-line basis over a period of seven or ten years.

Intangible assets are tested for impairment whenever events or circumstances indicate that a carrying amount may not be recoverable. An impairment loss would be recognized when the carrying amount of an asset exceeds the estimated undiscounted cash flows used in determining the fair value of the assets. The amount of the impairment loss to be recorded is calculated by the excess of the assets carrying value over its fair value. Fair value is determined using a discounted cash flow analysis.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**(J) Goodwill**

Goodwill represents the excess of the cost of investments in subsidiaries over the fair value of the net identifiable assets acquired. The Company reviews the goodwill of all of its reporting units on at least an annual basis to ensure its fair value is in excess of its carrying value in the financial statements. Any impairment in the value of goodwill is charged to income in the period such impairment is determined.

**(K) Revenue Recognition**

The Company recognizes revenue, net of estimated provisions for returns, rebates and sales allowances, from the sale of pharmaceutical products, at the time when the product is delivered to the customer. Revenues are recognized only when the Company has transferred to the customer the significant risk and rewards of ownership of the goods, title to the products transfers, the amount is fixed and determinable, evidence of an agreement exists, there is reasonable assurance of collection of the sales proceeds, the Company has no future obligations and the customer bears the risk of loss.

**(L) Advertising Costs**

Advertising costs are expensed as incurred. Advertising expense totaled \$30,590 and \$25,946 for the years ended December 31, 2006 and 2005, respectively.

**(M) Research and Development**

Research and development costs related to both present and future products are expensed as incurred. Total expenditures on research and development charged to general and administrative expenses for the years ended December 31, 2006 and 2005 were \$85,562 and \$96,347, respectively.

**(N) Income Taxes**

The Company accounts for income taxes under the Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes ( Statement 109 ). Under Statement 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates



expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under Statement 109, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company's subsidiary, Shanxi Weiqida is registered in a special economic region in China. This economic region allows foreign enterprises a two-year income tax exemption from central government tax beginning in the first year after they become profitable, being the year commencing on January 1, 2003 to December 31, 2004 and a 50% income tax reduction for the following three years, being 2005 to 2007. Shanxi Weiqida was approved as a wholly owned foreign enterprise in October 2002.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

Pursuant to a new regulation, No. 7 enacted during 2006 by the Shanxi Provincial Government, Shanxi Weiqida is eligible to be exempted from the Provincial income tax, which is 3% of the taxable income from 2006 to 2012.

Pursuant to the Chinese Corporate Income Tax Law approved on March 16, 2007, the applicable income tax rate for Shanxi Weiqida will be 25% of the taxable income from January 1, 2008.

**(O) Foreign Currency Translation**

Shanxi Weiqida, Huaxin and Dragon Pharmaceutical (Canada) Inc. maintain their accounting records in their functional currencies (Renminbi Yuan, Renminbi Yuan and Canadian dollar, respectively), however, the Company's functional and reporting currency is U.S. dollars. The financial statements of the Company's subsidiaries having a functional currency other than US dollars are translated into United States dollars using period end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transaction occurred. Net gains and losses resulting from foreign exchange translations are included in the statements of operations and stockholder's equity as other comprehensive gain (loss). Foreign currency exchange gains and losses on transactions occurring in a currency other than the Company's functional currency are included in the determination of net income in the period.

**(P) Other Comprehensive Income**

The Company has adopted SFAS No. 130, "Reporting Comprehensive Income", which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing comprehensive income in its Consolidated Statement of Operations and accumulated other comprehensive income in its Statement of Stockholders' Equity. Comprehensive income comprises all changes in equity for the period except those resulting from investments by owners and distributions to owners.

**(Q) Segments**

The Company operates in three reportable segments, Chemical Division, Pharma Division and Biotech Division.

**(R) Earnings Per Share**

Earnings per share are computed using the weighted average number of shares outstanding during the period. Diluted earnings per share, as determined using the treasury stock method, is equal to the basic income per share as common stock equivalents consisting of options to acquire 5,312,500 and 6,737,500 common shares that are outstanding at December 31, 2006 and 2005, respectively, are not dilutive.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**(S) Stock Based Compensation**

In December 2004, the FASB issued SFAS No. 123(R), "Accounting for Stock-Based Compensation". SFAS 123(R) establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. This Statement focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions. SFAS 123(R) requires that the fair value of such equity instruments be recognized as expense in the historical financial statements as services are performed. Prior to SFAS 123(R), only certain pro-forma disclosures of fair value were required.

SFAS 123(R) was adopted by the Company using the modified prospective transition method beginning January 1 2006. The Company estimated a 0% forfeiture rate by considering the historical employee turnover rates and expectations about the future, and will subsequently adjust compensation cost for differences between expectations and actual experience. Accordingly during the year ended December 31, 2006, the Company recorded a non-cash stock based compensation expense for awards granted prior to, but not yet vested, as of January 1, 2006, as if the fair value method required for pro forma disclosure under FAS 123 were in effect for expense recognition purposes. This resulted in \$387,206 being charged to income during the year ended December 31, 2006. The effect of the adoption of SFAS 123(R) on the Company's consolidated financial statements for the year ended December 31, 2006 is an increase in the loss from continuing operations and loss before income taxes and a decrease in net income of \$387,206. The adoption of SFAS123(R) had no effect on the cash flow from operations, cash flow from financing activities and basic and diluted earnings (loss) per share.

**(T) Recent Accounting Pronouncements**

In July 2006, FASB issued Interpretation No. 48. This Interpretation clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with SFAS Statement No. 109, "Accounting for Income Taxes". This Interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This Interpretation also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. This Interpretation is effective for fiscal years beginning after December 15, 2006. The Company currently is assessing the impact of Interpretation No. 48 on results of operations and financial position.



**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

In September 2006, FASB issued SFAS No. 157, Fair Value Measurements . The objective of SFAS 157 is to increase consistency and comparability in fair value measurements and to expand disclosures about fair value measurements.

SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The provisions of SFAS 157 are effective for fair value measurements made in fiscal years beginning after November 15, 2007. The Company has not determined the effect, if any, that the adoption of SFAS 157 will have on the Company's consolidated financial position or results of operations.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities ( SFAS No. 159 ). SFAS No. 159 permits entities to choose to measure many financial assets and financial liabilities at fair value. Unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. The Company currently is assessing the impact of SFAS No. 159 on its consolidated financial position or results of operation.

In September 2006, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial statements ( SAB No. 108 ), which provides interpretive guidance on the consideration of the effects of prior year misstatements in quantifying current year misstatements for the purpose of a materiality assessment. SAB No. 108 is effective as of the end of the Company s 2006 fiscal year, allowing a one-time transitional cumulative effect adjustment to beginning retained earnings as of January 1, 2006 for errors that were not previously deemed material, but are material under the guidance in SAB No. 108. The adoption of SAB 108 did not have an impact on the Company s financial statements.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 2**

**ACCOUNTS RECEIVABLE**

Accounts receivable at December 31, 2006 and December 31, 2005 consisted of the following:

	December 31, 2006	December 31, 2005
Trade and other receivables	\$ 4,958,311	\$ 4,796,578
Less: allowance for doubtful accounts	705,841	444,342
Accounts receivable, net	\$ 4,252,470	\$ 4,352,236

For the year ended December 31, 2006, the Company recorded a provision for doubtful accounts of \$243,697 in the Consolidated Statements of Operations compared to \$170,093 for the year ended December 31, 2005.

**NOTE 3**

**INVENTORIES**

Inventories at December 31, 2006 and December 31, 2005 consisted of the following:

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

	December 31, 2006	December 31, 2005
Raw materials	\$ 3,735,622	\$ 1,303,982
Work-in-progress	2,665,054	5,334,176
Finished goods	5,055,394	3,502,667
	11,456,070	10,140,825
Less: provision for obsolescence	236,161	608,288
	\$ 11,219,909	\$ 9,532,537

For the year ended December 31, 2006, the Company recorded a recovery from obsolete inventories of \$321,063, in the Consolidated Statements of Operations compared to \$330,049 for the year ended December 31, 2005.



**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS****FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005****Expressed in US Dollars****NOTE 4****PROPERTY AND EQUIPMENT**

The following is a summary of property and equipment at December 31, 2006 and December 31, 2005:

		December 31, 2006	
	Cost	Accumulated Depreciation	Net Book Value
Plant and equipment	\$ 46,994,977	\$ 10,821,927	\$ 36,173,050
Land use rights and buildings	17,203,965	783,079	16,420,886
Motor vehicles	658,523	123,647	534,876
Furniture and office equipment	2,287,291	1,018,891	1,268,400
Leasehold improvements	8,496	3,616	4,880
Construction in progress	8,279,113	-	8,279,113
	\$ 75,432,465	\$ 12,751,160	\$ 62,681,205

		December 31, 2005	
	Cost	Accumulated Depreciation	Net Book Value
Plant and equipment	\$ 43,726,412	\$ 6,580,534	\$ 37,145,878
Land use rights and buildings	15,861,498	454,054	15,407,444
Motor vehicles	573,032	186,364	386,668
Furniture and office equipment	2,111,165	801,879	1,309,286
Leasehold improvements	1,020,949	1,018,504	2,445
Construction in progress	6,902,234	-	6,902,234
	\$ 70,195,290	9,041,335	61,153,955

Depreciation expense for the years ended the December 31, 2006 and 2005 was \$ 5,113,545 and \$4,810,124, respectively. Land use rights and equipment with a net book value of \$25.5 million are pledged as collateral for \$18.6 million in loans payable (Note 9).

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 5**

**ACQUISITION OF ORIENTAL WAVE HOLDINGS LIMITED**

The Company completed the acquisition of Oriental Wave on January 12, 2005 whereby the Company issued 44,502,004 common shares in exchange for all of the issued and outstanding shares of Oriental Wave. The acquisition represented an important strategic step in strengthening the competitive position of the Company. The transaction was approved by the Company's shareholders and the regulatory authorities, who also approved an increase in the authorized share capital to 200,000,000 common shares.

This transaction resulted in the former shareholders of Oriental Wave owning 68.35% of the issued and outstanding shares of the combined entity as of January 12, 2005. Accounting principles applicable to reverse acquisition have been applied to record the acquisition. Under this basis of accounting, Oriental Wave is considered as the acquirer and, accordingly, the consolidated entity is considered to be a continuation of Oriental Wave with the net assets of the Company deemed to have been acquired and recorded at its fair market value of approximately \$7.9 million. The statement of operations includes the results of Oriental Wave for the year ended December 31, 2006 and 2005 and those of the Company from January 13, 2005.

The allocation of the net assets acquired is as follows:

Cash and cash equivalents	\$	2,103,481
Accounts receivable		1,527,554
Inventories		549,189
Prepaid and deposits		100,421
Total Current Assets		4,280,645
Property and equipment		785,742
Intangible assets		3,380,222
In-process research and development		265,000
Goodwill		965,000
Total Assets		9,676,609
Less accounts payables and accrued liabilities		(1,738,863)
Net assets acquired	\$	7,937,746

The intangible assets consist of the production technology and license and customer base acquired and are being amortized over a period of seven years. The in-process research and development costs of \$265,000 were written-off to other expense subsequent to the acquisition.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB  
**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 6**

**INTANGIBLE ASSETS**

Intangible assets consist of the following as of December 31, 2006 and December 31, 2005:

	December 31, 2006	December 31, 2005
Production technology	\$ 1,670,223	\$ 1,670,223
Product licenses	663,847	598,327
Customer base	1,160,000	1,160,000
	3,494,070	3,428,550
Less: accumulated amortization	915,212	443,556
	\$ 2,578,858	\$ 2,984,994

Amortization expense for years ended December 31, 2006 and 2005 was \$494,609 and

\$467,959 respectively. Amortization expense over the next five years will be approximately \$501,000 per year.

**NOTE 7**      **ASSETS HELD FOR SALE**

The Company signed two agreements on June 29, 2006 agreeing (1) to dispose part of its formulation business ( Sales of Formulation Business ) and (2) to deliver international registration documentation and services on a related product ( Registration Documentation ), to an unaffiliated party to the Company.

With the Sales of Formulation Business agreement, the Company agreed to dispose of its formulation production facilities located in the Economic Development Zone in Datong, China, 258 drug approvals from the Chinese State Food and Drug Administration ( SFDA ), the entire related hospital direct sales team for the formulation business and related inventories, account receivables and account payables, (or collectively Net Working Capital ). The Sales of Formulation Business became effective on July 1, 2006. According to the agreement, the buyer will not assume or have any responsibility for any obligation or liability in connection with any of the assets purchased arising prior to the completion of delivery of the assets purchased, including, any environmental liabilities or contamination which arise or result, directly or indirectly, from operation and use of any assets purchased. The proceeds for this agreement was \$ 13.32 million comprising \$8.20 million in cash and the assumption of \$5.12 million in long-term liabilities.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

With the Registration Documentation agreement, the Company agreed to provide certain international registration documentation and assistance to complete the registration. On July 28, 2006, the Company amended the Registration Documentation agreement. The proceeds for this agreement, which was completed in September, 2006, was \$1,500,000 in cash which was received in the third quarter of 2006. The amended Agreement expanded the scope and coverage which will allow the Company to provide additional international registration documentation and assistance to complete the registration in other market areas. The fees related to the expanded scope will be negotiated and determined in the future.

The total proceeds for these two agreements in aggregate were approximately \$14 million.

The assets of the formulation business sold and the liabilities assumed as at the date of sale on July 1, 2006 and as at December 31, 2005 are noted below. The balances as at December 31, 2005 were reclassified on the balance sheet as assets and liabilities held for sale.

	July 1, 2006	December 31, 2005
Accounts receivable	\$ 4,599,699	\$ 3,554,484
Inventories	3,202,877	4,599,198
Prepaid expenses	379,248	116,747,
Current assets disposed	8,181,824	8,270,429
Property and equipment	7,650,363	8,073,733
Intangible assets	353,877	382,072
Non-current assets disposed	8,004,240	8,455,805
Total assets disposed	16,186,064	16,726,234
Accounts payable	3,196,095	4,144,410
Accrued retirement benefits	83,986	90,714

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Other payables and accrued liabilities	2,878,699	4,229,263
Current liabilities assumed	6,158,780	8,464,387
Long term retirement benefits	545,729	620,396
Loans payable - long term	5,120,839	5,080,545
Long-term liabilities assumed	5,666,568	5,700,941
Total liabilities assumed	11,825,348	14,165,328
Net assets of formulation business disposed	\$ 4,360,716	\$ 2,560,906



**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

The operations of the formulation business sold have been reclassified and are presented in the consolidated financial statements as discontinued operations. A summary of such discontinued operations of the formulation business is as follows:

	Year Ended December 31, 2006	Year Ended December 31, 2005
Net sales	\$ 8,480,039	\$ 21,188,474
Cost of sales	5,214,471	11,725,812
Gross Profit	3,265,568	9,462,662
Operating and other expenses	2,211,723	4,437,310
Income before taxes	1,053,845	5,025,352
Income tax expense	(135,324)	(528,206)
Income from discontinued operations	918,521	4,497,146
Gain on disposal of assets before income taxes	4,933,884	-
Income tax expense	(714,488)	-
Gain on disposal of assets	4,219,396	-
Income from discontinued operation	\$ 5,137,917	\$ 4,497,146

**NOTE 8**

**OTHER PAYABLES AND ACCRUED LIABILITIES**

Other payables and accrued liabilities at December 31, 2006 and December 31, 2005 consist of the following:

	December 31, 2006	December 31, 2005
Machinery and equipment payable	\$ 8,299,839	\$ 10,202,637
Non-interest bearing demand loans	2,037,736	1,416,357
Current portion of long term payables	1,403,915	-
Accrued expenses	1,187,937	861,615
Value added tax payables	93,659	277,052
Income taxes payable	319,250	144,499
Other taxes payable	986,234	159,809
Deposits received from customers	1,008,876	636,433
	\$ 15,337,446	\$ 13,637,203

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 9****LOANS PAYABLE**

The loans payable, denominated in Renminbi Yuan, are as follows:

	December 31, 2006	December 31, 2005
RMB 30 million loan payable to a bank, interest rate of 6.138% per annum, collateralized by property and equipment and due May 2006	\$ -	\$ 3,717,472
RMB 5 million loan payable to a bank, interest rate of 7.254% per annum, collateralized by property and equipment and due September 2006	-	619,579
RMB 1.68 million loan payable to a bank, interest rate of 7.254% per annum, collateralized by property and equipment and due September 2006	-	208,178
RMB 4.8 million loan payable to a bank, interest rate of 8.874% per annum, guaranteed by an unrelated third party, due April 2006	-	594,796
RMB 52.3 million loan payable to a bank, interest rate of 6.912% per annum, collateralized by property and equipment with a net book value of \$8,878,104, due November 2006	-	6,480,793
RMB 55 million loan payable to a bank, interest rate of 6.336% per annum, collateralized by property and equipment with a net book value of \$9,027,894, due	-	6,815,366

April 2007

RMB 20 million loan payable to a bank, interest rate of 6.138% per annum, collateralized by property and equipment with a net book value of \$9,587,611, due January 2007\*

2,558,363 -

RMB 4.35 million loan payable to a bank, interest rate of 7.905% per annum, guaranteed by an unrelated third party, due April 2007

556,444 -

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

RMB 3.78 million loan payable to a bank, interest rate of 7.344% per annum, collateralized by property and equipment with a net book value of \$1,075,470, due September 2007	483,530	-
RMB 2.9 million loan payable to a bank, interest rate of 7.344% per annum, collateralized by property and equipment with a net book value of \$1,455,420, due September 2007	370,963	-
RMB 15 million loan payable to a bank, interest rate of 7.956% per annum, collateralized by property and equipment with a net book value of \$2,773,565, due September 2007	1,918,772	1,858,736
RMB 52.3 million loan payable to a bank, interest rate of 7.956% per annum, collateralized by property and equipment with a net book value of \$11,110,851, due December 2007	6,690,118	-
RMB 55 million loan payable to a bank, interest rate of 8.19% per annum, collateralized by Land and building with a net book value of \$9,099,032, due September, 2008	7,035,497	-
RMB 1.7 million (December 31, 2005 - 24.8 million) loan payable to a company, non-interest bearing and uncollateralized, due December 31, 2007	220,855	2,700,485
	19,834,542	22,995,405
Less current maturities	12,799,045	13,479,554
	\$ 7,035,497	\$ 9,515,851

Maturities are as follows:

Fiscal year ended December 31,		
2007	\$	12,799,045
2008		7,035,497
	\$	19,834,542

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

\* The loan payable due in January 2007 has been paid, and a RMB 20 million new loan from the same bank at interest rate of 7.956% and a due date of January 2008 was renegotiated and borrowed. (See note 20 (A)).

\*\* A RMB 25 million new bank loan was borrowed subsequent to December 31, 2006. (See note 20 (B)).

**NOTE 10**

**NOTES PAYABLE**

The company has a banking facility whereby the bank had issued several non-interest bearing notes payables to a vendor totalling \$3,327,829 as at December 31, 2005. These notes were repaid by July 2006 and the bank deposits used as collateral released.

**NOTE 11**      **DUE TO RELATED PARTIES**

The amounts due to related parties at December 31, 2006 and December 31, 2005 are unsecured and non-interest bearing:

	December 31, 2006	December 31, 2005
\$	107,227	\$ -

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Due to a company owned by a stockholder and director

Due to the spouse of a stockholder and director - 61,993

Due to a company owned by a stockholder and director

146 -

107,373 61,993

Less: current maturities

107,373 61,993

\$ - \$ -

49



**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 12**

**LONG TERM ACCOUNTS PAYABLE**

	December 31, 2006	December 31, 2005
Non interest bearing amounts payable to contractors related to the acquisition of plant and equipment. The amounts have been discounted using a rate of 6.5% as a result of term modifications made in 2005. The discount has been applied against the cost of the plant and equipment acquired. Due dates range from April 30, 2007 through December 31, 2008.		
Future annual payments are as follows:		
2007	\$ 1,458,457	\$ 1,855,261
2008	4,509,707	12,409,757
	5,968,164	14,265,018
Less: debt discount	514,387	2,048,186
	5,453,777	12,216,832
Less current maturities included in other payables and accrued liabilities (note 8)	1,403,915	-
	\$ 4,049,862	\$ 12,216,832

The Company accreted interest of \$1,567,000 and \$144,741 during the years ended December 31, 2006 and 2005, respectively.

**NOTE 13**

**SEGMENTS**

The Company operates in three reportable segments, the Pharma Division, Chemical Division and Biotech Division. The Pharma Division produces generic drugs with a focus on cephalosporin antibiotics and freeze-dry injectables. The Chemical Division produces certain bulk intermediate or ingredient to sell to other pharmaceutical companies for further processing and formulation into finished products. The Biotech Division produces Erythropoietin or EPO, an injection that stimulates red blood cell. The accounting policies of the segments are the same as described in the summary of significant accounting policies. The Company evaluates segment performance based on gross profit. All sales by division were to external customers (see Note 19 also). Sales relating to the Chemical Division's 7-ACA product represented approximately 75% of the division's sales for the year ended December 31, 2006 (2005 - 67%). Substantially all of the Company's assets are located in China. The following is a summary of the Company's segment information for the years ended December 31, 2006 and 2005 and as of December 31, 2006 and December 31, 2005.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

	Chemical Division	Pharma Division	Biotech Division	Total
<b>2006</b>				
Sales	\$ 45,799,773	\$ 6,610,325	\$ 2,455,707	\$ 54,865,805
Gross profit	9,093,481	(843,507)	1,765,172	10,015,146
Depreciation and amortization	4,839,917	-	768,237	5,608,154
<b>As at December 31,</b>				
<b>2006</b>				
Total assets	\$ 68,325,089	\$ 8,138,858	\$ 7,508,265	\$ 83,972,212
Additions to long-lived assets	3,618,711	45,760	1,854,917	5,519,388
Goodwill	-	-	965,000	965,000
Intangible assets	107,835	-	2,471,023	2,578,858
<b>2005*</b>				
Sales	\$ 27,326,459	\$ 3,895,537	\$ 3,834,324	\$ 35,056,320
Gross profit	1,084,543	619,310	2,782,440	4,486,293
Depreciation and amortization	4,394,294	-	883,789	5,278,083
<b>As at December 31,</b>				
<b>2005</b>				
Total assets (excluding assets held for sale)	\$ 75,831,748	\$ 875,317	\$ 8,133,197	\$ 84,840,262
Additions to long-lived assets	10,238,939	-	1,800,151	12,039,090
Goodwill	-	-	965,000	965,000
Intangible assets	47,336	-	2,937,658	2,984,994

\* 2005 segment information has been reclassified from last year's disclosure due to the sales of formulation business (see Note 7).

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 14**

**OTHER INCOME**

**(A)**

**Cell Line Development**

The Company has contracted with a European institute of biotechnology to develop a proprietary cell line and production process technology for the Company to enter the European market. In January 2006, the Company disposed of the cell line, and all applicable obligations relating thereto, being developed for the Company to enter the European market. The cell line was sold to a Company controlled by a Director of the Company who was also the President of the Company prior to the transaction. The cell line had a carrying value of \$0 and was sold for \$1 million, resulting in a gain of \$1 million.

**(B)**

**Government grants**

During the year ended December 31, 2006, Shanxi Weiqida, a wholly-owned subsidiary of the Company, applied for, and received, non refundable grants of \$567,910 from the government of China for bringing in investment and new technology to Datong city, Shanxi Province, China.

**(C) Funds Released by Chinese Government Liquidator**

In July 2003, the Company, through Shanxi Weiqida, acquired out of bankruptcy the Land Use Rights of a state-owned enterprise. After entering into this transaction, the Company was approached by an unrelated state agency to administer certain benefits payable to former employees of the agency (the government liquidator) as the Company had already established an infrastructure to make payments to these employees for settlement of liabilities related to the transaction. As a result, during 2004, the Company received \$1,751,208 from the government liquidator, for the settlement of human resources related expenses of the bankrupt enterprise. As well, during the first quarter of 2005, a separate municipal agency, the Datong Municipal Government, approved the transfer of a fund with a balance of \$140,036 originally reserved for the employee housing welfare as part of the liquidation process of the state-owned

enterprise. The two agencies, unrelated to the acquisition, allowed the Company to retain the cash balance of \$745,828 as well as the reserve of \$140,036 as payment for services provided by the Company. As a result, the Company recorded other income of \$885,864 during 2005 to reflect the above transactions.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 15**

**COMMITMENTS AND CONTINGENCIES**

**(A) Employee Benefits**

The full time employees of Shanxi Weiqida are entitled to employee benefits including medical care, worker compensation, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for those benefits based on certain percentages of the employees' salaries. The total provision for such employee benefits was \$435,445 and \$177,775 for the years ended December 31, 2006 and 2005, respectively. The Company is required to make contributions to the plans out of the amounts accrued for medical and pension benefits. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.

**(B) Loan Guarantee**

The Company has guaranteed a bank loan to a supplier in the amount of \$2,532,000 (RMB19.8 million) due on July 9, 2007. Interest on the loan is charged at 9.945% and the bank has the right to seek settlement from the Company for payment should the supplier fail to repay the loan. There is no recourse or possible recovery for the Company should the supplier default on its bank loan. The maximum potential amount of future payments (undiscounted) that the Company could be required to make is \$2,660,000 (RMB 20.83 million). The Company provided the guarantees to the supplier to maintain a good business relationship.

The Company has also issued a guarantee to a bank as collateral for loans to a third party vendor of \$2,558,000 (RMB20 million) due on September 26, 2007 and \$3,837,000 (RMB30

million) due on October 27, 2007. Interest is charged at the bank's base rate plus 5.9475%. The bank has the right to seek settlement from the Company for payment should the third party vendor fail to repay the loan. The maximum potential amount of future payments (undiscounted) that the Company could be required to make is \$ 6,695,000

(RMB 52.34 million). This vendor has pledged certain property and equipment to the Company as collateral for this guarantee.

**(C) Capital Commitments**

According to the Articles of Association of Shanxi Weiqida, the Company is required to contribute \$19,704,877 (RMB 159,018,360) outstanding registered capital to Shanxi Weiqida within five years from December 16, 2003. As of December 31, 2006, the Company has fulfilled the registered capital requirement by transferring \$7,940,397 from retained earnings and \$766,355 from reserves to registered capital. Shanxi Weiqida has registered capital of \$24,175,305 (RMB 200,000,000).



**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

According to the Articles of Association of Beijing Weixiang, the Company is required to contribute registered capital of \$5,000,000 to Beijing Weixiang within five years from August 1, 2005. As of December 31, 2006, the Company has contributed \$1,098,683 of the registered capital requirement and has registered capital commitments of \$3,901,317.

**(D) Contingent Employment Benefits**

During July 2003, the Company acquired land and buildings from a government liquidator in exchange for assuming certain future employment, healthcare and land acquisition costs of the factory and its former employees. Under the terms of the contract with the liquidator, the Company will remain contingently liable for these liabilities until the earliest of date of retirement, re-employment or death for each employee. However, as part of the sale of formulation business completed on July 1, 2006, the Company transferred these liabilities to the buyer (also see Note 7). The Company is no longer contingently liable for these liabilities.

**(E) Operating Leases**

The Company has entered into an operating lease agreement for its administrative offices in Vancouver for an amount escalating from CDN\$73,000 to CDN\$78,000 (US\$62,600 to US\$66,500) per annum until March 31, 2011. The Company has subleased its previous office space which is leased until March 31, 2007. The total minimum payments required under both leases are as follows:

2007	\$ 64,380
2008	\$ 64,380
2009	\$ 66,500
2010	\$ 66,500
Thereafter	\$ 16,570
	\$ 278,330

The rent expense for the year ended Decemer 31, 2006 was \$123,421 (net of \$126,917 sublease income) (2005 - \$188,725, net of \$nil sublease income).

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 16**

**STOCKHOLDERS EQUITY**

**(A) Reserves**

Pursuant to PRC regulations, Shanxi Weiqida is required to make appropriations to reserves funds, comprising the reserve fund, staff welfare fund and enterprise expansion fund, based on after-tax net income determined in accordance with generally accepted accounting principles of the People's Republic of China (the PRC GAAP). Appropriations to the reserve fund should be at least 10% of the after tax net income determined in accordance with the PRC GAAP until the reserve is equal to 50% of Shanxi Weiqida's registered capital. The reserve fund is established for covering potential losses. Appropriations to the staff welfare fund are at a percentage, as determined by the Board of Directors, of the after tax net income determined in accordance with the PRC GAAP.

The staff welfare fund is established for the purpose of providing employee facilities and other collective benefits to the employees. Appropriations to the enterprise expansion fund are made at the discretion of the Board of Directors. The enterprise expansion fund is established for expanding business operation. The reserve fund and enterprise expansion fund are recorded as part of shareholders' equity but are not available for distribution to shareholders other than in liquidation, while the staff welfare fund is recorded as a liability and is not for distribution to shareholders. The appropriations to reserves are made by the Board of Directors on an annual basis.

During the third quarter ended September 31, 2006, in order to fulfil Shanxi Weiqida's registered capital requirement, the Company transferred \$7,940,397 from retained earnings and \$766,355 from reserves to registered capital. By September 30, 2006, Shanxi Weiqida has registered capital of \$24,175,305 (RMB 200,000,000). (See note 15 (C))

During the year ended December 31, 2006 the Company appropriated reserves of \$838,762 and staff welfare fund of \$6,989 based upon the current year's net income after tax.

During the year ended December, 2005, the Company transferred \$5,204,022 in excess appropriation made in prior years from reserves to retained earnings. The Company also appropriated reserves of \$286,701 based upon the Company's 2005 net income after tax.

**(B) Stock Options**

The Company has adopted the 2005 Stock Option Plan, effective August 13, 2005, which allows for the granting of options to Directors and Employees for a period of up to ten years. The Company did not grant any options during the year ended December 31, 2006. During the year ended December 31, 2005, the Company granted options to its directors and employees to purchase 5,920,000 shares at a weighted average price of \$0.91 per share, with 2,260,000 shares at an exercise price of \$1.18 (being the market price at the time) expiring on January 12, 2010 and 3,660,000 shares at an exercise price of \$0.74 (being the market price at the time) expiring on September 30, 2010. Options to purchase 4,320,000 shares vested immediately with 400,000 options vesting on January 12, 2006, 400,000 options vesting on September 30, 2006, 400,000 options vesting on January 12, 2007 and the balance of 400,000 options vesting on September 30, 2007. As of December 31, 2006, options to purchase 980,000 shares from the grants in 2005 were forfeited or cancelled.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB  
**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

The following table summarizes stock option information for the year ended December 31, 2005 and 2006:

	Shares	Weighted Average Exercise Price
Options outstanding at December 31, 2004	1,749,000	\$ 2.36
Granted	5,920,000	\$ 0.91
Expired	(241,000)	
Forfeited	(990,500)	\$ 2.93
Options outstanding at December 31, 2005	6,437,500	\$ 0.92
Granted	0	-
Forfeited	(725,000)	\$ 1.09
Cancelled	(400,000)	
Options outstanding at December 31, 2006	5,312,500	\$ 0.74
		0.91

Options Outstanding  
Weighted

Options Exercisable  
Weighted

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Range of Exercise Prices	Number Outstanding	Average Remaining Contractual Life	Weighted Average Exercise Price	Number Exercisable	Average Remaining Contractual Life	Weighted Average Exercise Price
\$0.68 - \$0.74	3,395,000	3.55	\$0.74	3,195,000	3.54	\$0.73
\$1.18 - \$1.70	<u>1,917,500</u>	<u>2.90</u>	<u>\$1.21</u>	<u>1,667,500</u>	<u>2.88</u>	<u>\$1.21</u>
	5,312,500	3.31	\$0.91	4,862,500	3.31	\$0.90

Aggregate intrinsic value of the Company's stock options is calculated as the difference between the exercise price of the options and the quoted price of the Company's common shares that were in-the-money. As of December 31, 2006 and 2005 there was no intrinsic value to the Company's stock options exercisable or outstanding as none of the options were in-the-money. The estimated fair value of stock options vested during the years ended December 31, 2006 and 2005 was \$258,477 and nil. There is approximately \$42,910 of unrecognized compensation expense as of December 31, 2006 that is expected to be recognized over of the next six months.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

SFAS 123(R) was adopted by the Company effective as of the beginning of fiscal 2006, on a modified prospective basis, whereby the Company records a non-cash stock based compensation based upon the fair value of the options at the time they are granted. The Company estimated a 0% forfeiture rate by considering the historical employee turnover rates and expectations about the future, and will subsequently adjust compensation cost for differences between expectations and actual experience. During the year ended December 31, 2006, options to purchase 300,000 shares were forfeited and \$103,594 compensation cost was reversed. Also, during the year ended December 31, 2006, options to purchase 400,000 shares were cancelled without the concurrent grant of a replacement award, which was accounted for as a repurchase for no consideration. Accordingly, \$128,729 compensation cost was recognized at the cancellation date. This resulted in \$387,206 relating to general and administrative expenses being charged to income during the year ended December 31, 2006. The company continued to use the straight-line amortization method to recognize compensation expense.

The Company previously accounted for its stock-based compensation plan in accordance with APB Opinion No. 25, under which no compensation was recognized in connection with options granted to employees and directors except if options were granted with a strike price below fair value of the underlying stock. The Company adopted the disclosure requirements SFAS No. 123, Accounting for Stock-Based Compensation. Accordingly, the Company is required to calculate and present the pro forma effect of all awards granted. The fair value of each option granted to an employee was estimated as of the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: risk-free interest rate of 5.5%, dividend yield 0%, volatility of 90%, and expected lives of approximately 5 years. The volatility was computed based on historical stock prices. The expected life is computed based on historical experience, giving consideration to the contractual terms of the stock based awards and vesting schedules. The risk-free interest rate is the U.S. Treasury rate having a term equal to the expected life of the option in effect at the time of grant. The weighted average fair value of the options granted was \$0.69 for the options granted in January 2005 and \$0.43 for the options granted in September 2005. Based on the computed option values and the number of the options issued, had the Company recognized compensation expense in the prior period the following would have been its effect on the Company's net income and earnings per share:

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

Income (Loss) for the year ended December 31, 2005:	
- as reported from continuing operations	(\$4,314,576)
- deduct: total stock-based employee compensation determined under fair value based method	(\$2,494,016)
- pro-forma net loss from continuing operations	(\$6,808,592)
- as reported from discontinued operations	\$4,497,146
- deduct: total stock-based employee compensation determined under fair value based method	-
- pro-forma net income from discontinued operations	\$4,497,146
- as reported net income	\$182,570
- deduct: total stock-based employee compensation determined under fair value based method	(\$2,494,016)
- pro-forma net loss	(\$2,311,446)
Basic and diluted income (loss) per share:	
- as reported from continuing operations	(\$0.07)
- as reported from discontinued operations	\$0.07
- as reported net loss	\$0.00
- pro-forma from continuing operations	(\$0.11)
- pro-forma from discontinued operations	\$0.07
- pro-forma net loss	(\$0.04)

**NOTE 17**

**INCOME TAXES**

Shanxi Weiqida and Huaxin are subject to income taxes in China on their taxable income as reported in their statutory accounts at a tax rate in accordance with the relevant income tax laws.



Oriental Wave, Allwin Newtech Ltd. and Allwin Biotrade Inc are British Virgin Islands ( BVI ) companies and are not subject to income taxes. During the year, the three BVI companies elected to be treated as disregarded entities in the U.S. After this election, the three BVI companies would be viewed as branches of Dragon Pharmaceutical Inc. and be subject to taxes in the U.S.

Dragon Pharmaceutical Inc. and Dragon Pharmaceutical (Canada) Inc. are U.S. and Canadian companies, respectively, and are subject to taxes in those jurisdictions.

**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

On March 16, 2007, The National People's Congress of China passed The Law of the People's Republic of China on Enterprise Income Tax (the Enterprise Income Tax Law). The Enterprise Income Tax Law will become effective on January 1, 2008. This new law eliminated the existing preferential tax treatment that is available to the foreign invested enterprises (FIEs) but provides grandfathering of the preferential tax treatment currently enjoyed by the FIEs.

Under the new law, both domestic companies and FIEs are subject to a unified income tax rate of 25%. Shanxi Weiqida and Huaxin are currently enjoying the tax holiday. Both companies may be able to preserve its tax holiday under the grandfathering provisions in the Enterprise Income Tax Law. However, as detailed implementation rules were not available at the time the Enterprise Income Tax Law was passed, the Company will continue to monitor the implementation rules of the grandfathering provisions of the new law.

The Company has structured its business and operations on an international basis. The Company's history is that they have also been involved in a number of business combinations. As a result the Company could be involved in various investigations, claims and tax reviews that arise in the ordinary course of business activities. Each of these matters is subject to various uncertainties and it is possible that some of these matters may be resolved unfavorably to the Company. The Company has established an accrual for matters that are probable and can be reasonably estimated. Management believes that any liability that may ultimately result from the resolution of these matters in excess of amounts provided will not have a material adverse effect on the financial position or results of operations of the Company.

The tax effect of temporary differences that give rise to significant components of the deferred tax assets (liability) are as follows:

	December 31, 2006	December 31, 2005
Deferred tax assets		
Inventory	\$ 86,000	\$ 281,000
Property and equipment	2,106,000	2,532,000
Losses carried forward	1,600,000	3,707,000
Total deferred tax assets	3,792,000	6,520,000
Less: Valuation allowance	(3,383,000)	(4,818,000)
Net deferred tax assets	409,000	1,702,000
Deferred tax liabilities		
Other liabilities	(409,000)	(1,702,000)
Net deferred tax assets	\$ -	\$ -

The valuation allowance is reviewed periodically. When circumstance changes and this causes a change in management's judgment about the realizability of deferred tax assets, the impact of the change on the valuation

allowance is generally reflected in current income,

The Company has non-capital losses carried forward of approximately \$5 million in Canada, expiring between 2008 and 2026. Deductibility of the losses and period of expiration is subject to the normal review by taxation authorities.

All income and taxes are attributable to foreign and continuing operations. A reconciliation of the federal statutory income tax, at the statutory rate of 35% to the Company's effective income tax rate, for the years ended December 31, 2006 and 2005 are as follows:

	2006	2005
Loss from operations before taxes	\$ (779,376)	\$ (4,295,548)
Statutory tax rate	35 %	35%
Income tax expense (recovery) at statutory tax rates	(272,781)	(1,503,442)
Foreign tax rate differential	(209,079)	373,651
Expenses not deductible for income tax purposes	(81,062)	11,565
Tax exempted income	(150,887)	(147,314)
Non-recognition of benefit of loss carry forward	1,210,572	1,285,567
Benefit of prior year loss recognized	(341,045)	-
Foreign tax refund	(331,694)	-
Income tax expense (recovery)	\$ (175,976)	\$ 19,028

## **NOTE 18**

### **RELATED PARTY TRANSACTIONS**

During March 2005, \$2,415,458 of loans payable to an entity related to a director of the Company was converted into equity of the Company.

In January 2006, the Company disposed of the cell line, and all applicable obligations relating thereto, being developed for the Company to enter the European market, to a Company controlled by a Director of the Company who was also the President of the Company prior to the transaction for \$1 million. (See Note 14(A)).

As discussed in Note 7, on July 1, 2006, the Company disposed its formulation business to an unrelated party ( the Party ). Subsequent to the transaction, one of the Company's stockholders and directors became a director of the Party. During the year ended December 31, 2006, the Company supplied certain raw materials to the Party for which the Company charged \$889,963 and also used the Party as a contract manufacturer of certain Pharma Division products for which the Party charged \$1,281,492. As at December 31, 2006, the Company had a balance of \$107,227 due to the Party (see Note 11). The transactions are recorded at exchange amounts agreed to by the related parties.



**DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005**

**Expressed in US Dollars**

**NOTE 19**

**CONCENTRATIONS AND RISKS**

64% and 70% of the Company's revenues for the years ended December 31, 2006 and 2005, respectively, were derived from customers located in China. The Company had sales of \$14,451,791 in the Chemical Divisions to customers in India, representing 27.6% of the Company's revenues for the year ended December 31, 2006; while the Company had sales of \$6,593,391 and \$644,100 in the Chemical and Biotech divisions to customers in India, representing 13% of the Company's revenues for the year ended December 31, 2005. Substantially all of the Company's assets at December 31, 2006 and 2005 were located in China.

Sales to the Company's five largest customers accounted for approximately 58.5% and 52.7% of the Company's sales for the years ended December 31, 2006 and 2005, respectively; while sales to the Company's largest customer accounted for approximately 26.3% and 19.1%, respectively. Amounts owing from one customer represented 14.2% of the Company's trade and other receivables at December 31, 2006.

The Company is exposed to the risk arising from changing interest rates. A detailed analysis of the Company's Loans Payable, together with their respective interest rates and maturity dates, are included in Note 9.

The majority of the Company's assets, liabilities, revenues and expenses are denominated in Renminbi, which was tied to the US Dollar and is now tied to a basket of currencies of China's largest trading partners, is not a freely convertible currency. The appreciation of the Renminbi against the US Dollar would result in an increase in the assets, liabilities, revenues and expenses of the Company and a foreign currency gain included in comprehensive income. Conversely, the devaluation of the Renminbi against the US Dollar would result in a decrease in the assets, liabilities, revenues and expenses of the Company and a foreign currency loss included in comprehensive income. At December 31, 2006, approximately US\$1,014,362 of the cash and cash equivalents (December 31, 2005: US\$885,681) and all of the restricted cash as at December 31, 2005 are held in Renminbi.

**NOTE 20**

**SUBSEQUENT EVENTS**

(A) Subsequent to December 31, 2006, the Company entered into a loan agreement with a bank for \$2,558,363 (RMB 20 million) bearing interest at a rate of 7.956% per annum, collateralized by property and equipment with a net book value of \$9,587,611, and is due in January 2008.

(B) Subsequent to December 31, 2006, the Company entered into a loan agreement with a bank for \$3,197,953 (RMB 25 million) bearing interest at a rate of 6.732% per annum, collateralized by land and buildings with a net book value of \$10,022,386, and is due in February 2008.

(C) Subsequent to December 31, 2006, the Company borrowed money from an unrelated party for \$243,044, non-interest bearing and payable on demand.

**ITEM 8.**

**CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS AND**

**ACCOUNTING AND FINANCIAL DISCLOSURE.**

The Company was informed that Moore Stephens Ellis Foster Ltd., Chartered Accountants ("Moore Stephens"), who had served as our independent accountants for the year ended December 31, 2004, had entered into a transaction with Ernst & Young LLP (Canada) on May 3, 2005, under which certain assets of Ellis Foster were sold to Ernst & Young and the professional staff and partners of Ellis Foster joined Ernst & Young either as employees or partners of Ernst & Young and carry on their practice as members of Ernst & Young. On July 10, 2005, the Registrant's board of directors formally approved the engagement of Ernst & Young LLP as the Registrant's independent registered public accounting firm for 2005. On July 12, 2005, the former Moore Stephens representative who now carries his practice as a member of Ernst & Young informed the Registrant that the merger of Moore Stephens into Ernst & Young on May 3, 2005, effectively constituted their resignation as the Registrant's independent accountant responsible for auditing its financial statements, and that effective as of such date, Moore Stephens no longer acted as the Registrant's independent registered public accountant. For the year of 2005 and 2006, Ernst & Young LLP was engaged as the independent registered public accounting firm of the Registrant.

**ITEM 8A.**

**CONTROLS AND PROCEDURES.**

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, about the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(e). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Form 10-KSB are effective in timely alerting them to material information required to be included in this Form 10-KSB.

**ITEM 8B.**

**OTHER INFORMATION**

Nil.

## PART III

### ITEM 9.

#### **DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.**

The Company has eight directors consisting of Mr. Han, Mr. Weng, Ms. Liu, Dr. Wick, Dr. Sun, Mr. Mak, Mr. Frey and Mr. Li. who were all re-elected as directors at the annual meeting of shareholders held on May 11, 2006. The following describes the background for Mr. Han, Mr. Weng, Ms. Liu, Dr. Wick, Dr. Sun, Mr. Mak, Mr. Frey and Mr. Li.

#### **Description of Current Directors**

*Mr. Yanlin Han*, age 43, is the Chief Executive Officer and the Chairman of the Board of Director of Dragon, positions he assumed in January 2005. Prior to the reverse take-over of the Company, Mr. Han was the founder and Chairman of Oriental Wave and responsible for the overall strategic planning and direction of the Company. Mr. Han has over 20 years of experience in the pharmaceutical industry in many positions like material buyer, product sales and manager for state-own companies in China and has very extensive sales and production management experience in China. He founded his private company named Shanxi Tongling Pharmaceutical Company in 1994, which became the vehicle to acquire state-own pharmaceutical companies through bankruptcy process or contractual management agreements. Mr. Han set up a joint venture with a large Indian pharmaceutical company to produce pharmaceutical intermediates with mass fermentation technology. Mr. Han also serves as the Vice-President of Shanxi Province Foreign Investment Enterprise Association and Vice-President of Datong City Trade Council. Mr. Han graduated from Shanxi Institute of Economic Management in 1986.



**Mr. Zhanguo Weng**, age 52, had been a Director of the Company since January 2005. Mr. Weng was the Vice President, China Operation until July 1, 2006 when the Company completed the sales of part of its formulation business. Mr. Weng has over 25 years of experience in pharmaceutical industry including being the General Manager for Shanxi Tongzhen Pharmaceutical Co. Ltd. from August 1997 to January 2002 and Superintendent for Datong No. 2 Pharmaceutical Factory from June 1992 to August 1997. He graduated from the Business Administration faculty of Shanxi Broadcasting University in 1986 and has also participated the Senior Program of MBA (Pharmaceutical Line) of People's University of China for two years. Subsequent to the sales of part of the company's formulation business on July 1, 2007, Mr. Weng became a director of Shanxi Qianyuan Pharmaceutical Company, the buyer of the Company's formulation business.

**Ms. Xuemei Liu**, age 37, has been a Director of the Company since January 2005. Ms. Liu is currently the Chairman of Tera Science & Technology Development Co. Ltd. which engages in a wide range of investment projects in real estate development, coal trading and media and publishing industry. Prior to her present position as Chairman of Tera Science & Technology Development Co. Ltd., Ms. Liu was the vice general manager of Beijing Chemical Baifeng Investment Corporation Futures Broker Company from 1996 to 1999. Ms. Liu graduated from Beijing University with a Bachelor degree in 1996 and graduated from the Graduate School of the Chinese Academy of Social Sciences with a Master degree in 1998.

**Dr. Alexander Wick, Ph.D.**, age 69, has been a Director of Dragon since 1998 and was the President from 2002 until his resignation effective on February 2, 2006. Dr. Wick holds a doctorate degree in synthetic organic chemistry from the Swiss Federal Institute of Technology and has completed post-doctoral studies at Harvard University. He has had leading positions in the pharmaceutical research departments of F. Hoffmann-La Roche in the United States and Switzerland and Synthelabo in France (Director of Chemical Research and Development) for over 25 years in the field of antibiotics, prostaglandins, vitamins, cardiovascular CNS and AIDS. In 1995 he created the fine chemicals company Sylachim S.A., a 100% subsidiary of Synthelabo, active in chemical intermediates and APIs for the world's largest pharmaceutical companies (turnover of over 100 million Euros) and was its President until its acquisition by the German conglomerate mg Technologies (Dynamit-Nobel GmbH) in 2001.

**Dr. Yiu Kwong Sun, M.D.**, age 63, has been a Director of Dragon since 1999. Dr. Sun graduated from the University of Hong Kong Faculty of Medicine in 1967. He is a Founding Fellow of the Hong Kong College of Family Physicians and a Fellow of the Hong Kong Academy of Medicine. Since 1995, he has served as the Chairman of the Dr. Sun Medical Centre Limited, which has been operating a network of medical centers in Hong Kong and China for the past 20 years. He is also the Administration Partner of United Medical Practice, which manages a large network of medical facilities throughout Hong Kong and Macau. Dr. Sun has been a member of the Dr. Cheng Yu Tung Fellowship Committee of Management of the University of Hong Kong Faculty of Medicine since 1997.

**Mr. Peter Mak**, age 46, has been a Director of Dragon since January 2005, is a fellow of the Chartered Association of Certified Accountants in UK as well as a fellow of the Hong Kong Institute of Certified Public Accountant. Mr. Mak was formerly the Managing Partner of Arthur Andersen Southern China and also a partner of Arthur Andersen Worldwide. Through his twenty years of accounting and financial practices, Mr. Mak has extensive knowledge and experience in Chinese and international accounting standards. He is also the independent director or financial advisor

for several public companies listed in United States and Hong Kong. Mr.Mak also serves as Chief Financial Officer of New Dragon Asia Corp., a company whose shares are registered under the Securities Exchange Act of 1934.

**Mr. Heinz Frey**, age 69, has been a Director of Dragon since January 2005, graduated from University of Berne, Switzerland in 1966, has 30 years of experience in the telecommunication industry, security manufacturing and service industry. He has broad experience in the management of various sizes of companies with global presence, financing and controlling of international companies, leading development, production, sales and finance departments. He is also a board member of various companies.

**Mr. Jin Li**, age 39, has been a Director of Dragon since January 2005, is currently a senior advisor of Phycos International Co., Ltd. Prior to joining Phycos, he was a partner at the international law firm, Linklaters. Mr. Li studied biochemistry at Peking University in China and received his Master of Science degree in Biochemistry from the University of Michigan and his doctoral degree from Law School of University of Columbia. He has more than ten years of experience in international IPOs, M&A and business transactions.

### Description of Executive Officers

The following sets forth our executive officers.

<b>Name</b>	<b>Position</b>	<b>Age</b>
Yanlin Han	Chief Executive Officer	43
Zhanguo Weng	Vice President, China Operation until July1, 2006	52
Alexander Wick	President until February 2, 2006	69
Maggie Deng	Chief Operating Officer	39
Garry Wong	Chief Financial Officer	36

For a description of Mr. Han, Mr. Weng and Dr. Wick, please see their biographies above under "Description of Current Directors."

Maggie Deng is the Chief Operating Officer of the company since January 2005, holding bachelor degree from Tsinghua University in China. Ms. Deng has over 10 years of experience working in or with public companies as investment banker, mainly on IPOs and secondary offering for Chinese companies on domestic stock exchange as well as international ones. Ms. Deng was the senior manager of China International Capital Corporation, a Morgan Stanley joint venture investment banking firm in China, from 1998 to 2001. Ms. Deng moved to Canada in 2001 and held a position of Assistant to President in a start-up biotech company in Vancouver, Canada.

Garry Wong is the Chief Financial Officer of the Company since January 2005. Prior to his current position, Mr. Wong served as our Executive Assistant to President and CEO of the Company from February 2002 to January 2005. Before joining us, Mr. Wong was a team member of the Global Mergers and Acquisitions Group at Nortel

Networks since 1996. He managed and executed transactions consisting of acquisitions, divestitures, equity investments, spin-offs, public market listing and joint ventures, in Europe, North America, Asia and the Middle East. Mr. Wong is a Chartered Financial Analyst who received an International MBA degree from York University, Canada with double majors in Corporate Finance and Greater China studies and a Bachelor degree in Business Administration from University of Hong Kong.

### **Audit Committee**

On September 30, 2005, the Board appointed Mr. Mak, Mr. Frey and Mr. Li, each of which are independent directors, to the Audit Committee. Mr. Mak, the Chairman of the Audit Committee, is an expert within the meaning of Item 401 of Regulation S-B. The Audit Committee operates under a written charter.

### **Nominating Committee**

Due to the size of the Company, the Company does not have a separate nominating committee. Instead, the Board of Directors serves as the nominating committee. The Board of Directors will consider nominations to the Board by its shareholders. Requests for consideration should be made to the Company's Secretary, Maggie Deng.

### **Code of Ethics**

The Company has adopted a Code of Ethics that is applicable to the officers, directors and employees of the Company, including the Company's principal executive officer, principal financial officer, principal accounting officer, controller, or persons performing similar functions. The Code of Ethics is available on the Company's website at [www.dragonpharma.com](http://www.dragonpharma.com). Amendments to and waivers from the Code of Ethics will also be disclosed on the Company's website.

### **Compliance with Section 16 of the Securities Exchange Act of 1934**

Section 16(a) of the Exchange Act requires our executive officers and directors to file reports of ownership and changes in ownership of our common stock with the SEC. Executive officers and directors are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. Based solely upon a review of Forms 3, 4 and 5 delivered to us as filed with the Securities and Exchange Commission, we believe that our executive officers and directors and persons who own more than 10% of our common stock timely filed all required reports pursuant to Section 16(a) of the Exchange Act.

## **ITEM 10. EXECUTIVE COMPENSATION**

### **COMPENSATION DISCUSSION AND ANALYSIS**

#### **General Philosophy**

The Company's Board of Directors is responsible for establishing and administering the Company's executive and director compensation.

## **Executive Compensation**

The Board of Director s compensation objective is designed to attract and retain the best available talent while efficiently utilizing available resources. The Board compensates executive management consisting primarily of a base salary and equity compensation designed to be competitive with comparable employers in the location of countries in which it operates primarily China and Vancouver, Canada, and to align management s compensation with the long-term interests of shareholders. In considering executive management s compensation, the Board also takes into consideration the financial condition of the Company.

## **Compensation Summary**

The following table summarizes all compensation earned by or paid to our Chief Executive Officer ( Principal Executive Officer) and other executive officers, during the past two fiscal years.

### Summary Compensation Table

<u>Name and principal position</u>	<u>Year</u>	<u>Salary</u>	<u>Option Award</u>	<u>All Other compensation</u>	<u>Total</u>
Yanlin Han	2006	\$172,065	-	-	\$172,065
Chief Executive Officer					
	2005	\$156,263	\$215,000	-	\$371,263
Maggie Deng	2006	\$114,710	-	-	\$114,710
Chief Operating Officer					
	2005	\$104,175	\$224,000	-	\$328,175
Garry Wong	2006	\$114,710	-	-	\$114,710
Chief Financial Officer					
	2005	\$106,654	\$224,000	-	\$330,654

### Option Grants in 2005 and 2006

The Company did not grant any options during 2006.

For the year of 2005, the Company granted options to purchase 2,260,000 shares at an exercise price of \$1.18 per share on January 12, 2005 and 3,660,000 shares at an exercise price of \$0.74 per share on September 30, 2005.

### Aggregated Option Exercises in Last Fiscal Year and Ten-Year Options/SAR Repricings

There was no repricing of options for the fiscal year ended December 31, 2005 and 2006.

### Fiscal Year End Option Values

The following table sets forth for our executive officer named in the Summary Compensation Table the number and value of exercisable and un-exercisable options as at December 31, 2006.

## Number of Securities

## Underlying Unexercised Options

at December 31, 2006

<u>Name</u>	<u>Number of Securities</u>		<u>Option Exercise</u>	<u>Option Expiration</u>
	<u>Exercisable</u>	<u>Unexercisable</u>	<u>Price</u>	<u>Date</u>
Yanlin Han	500,000	-	0.74	Sept 30, 2010
	200,000		\$1.18	Jan 12, 2010
Maggie Deng		-		
	200,000		\$0.74	Sept 30, 2010
	20,000		\$1.70	Apr 25, 2007
Garry Wong	200,000	-	\$1.18	Jan 12, 2010
	200,000		\$0.74	Sept 30, 2010

**Director's Compensation**

Directors are not routinely compensated for their services. However, from time to time, Board members are awarded stock options as determined by the Board. The exercise price of the options is based on the fair market value of the underlying shares of common stock at the time of grant. No directors received any compensation during 2005 and 2006. At a directors meeting held on January 12, 2005, Ms. Liu, Dr. Sun and Dr. Wick were granted options to purchase 200,000, 200,000, and 400,000 shares of common stock, respectively, at \$1.18 per share which represented the closing per share price as of that date.



At a directors meeting held on September 30, 2005, Mr. Han, Mr. Weng, Ms. Liu, Dr. Wick,, Dr. Sun, Mr. Mak, Mr. Frey and Mr. Li were granted options to purchase 500,000, 300,000, 200,000, 400,000, 200,000, 200,000, 200,000 and 200,000 shares of common stock, respectively, at \$0.74 per share which represented the closing per share price as of that date. No directors received any option grant during 2006.

### Summary Compensation Table

<u>Name and principal position</u>	<u>Year</u>	<u>Option Award</u>	<u>All Other compensation</u>	<u>Total</u>
Zhanguo Weng	2006	-	-	-
	2005	\$129,000	-	\$129,000
Xuemei Liu	2006	-	-	-
	2005	\$224,000	-	\$224,000
Alexander Wick	2006	-	-	-
	2005	\$448,000	-	\$448,000
Yiu Kwong Sun	2006	-	-	-
	2005	\$224,000	-	\$224,000
Peter Mak	2006	-	-	-
	2005	\$86,000	-	\$86,000
Heinz Frey	2006	-	-	-
	2005	\$86,000	-	\$86,000
Jin Li	2006	-	-	-
	2005	\$86,000	-	\$86,000

#### ITEM 11.

#### SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table shows the amount of our common stock (symbol: TSX:DDD; OTCBB:DRUG; Berlin, Frankfurt and XETRA: DRP) beneficially owned (unless otherwise indicated) by each shareholder known by us to be the beneficial owner of more than 5% of our common stock, by our named executive officer and current directors and the executive officers and directors as a group. Except as otherwise indicated, all information is as of March 15, 2007

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

<u>Name of Beneficial Owner</u>	Shares	
	<u>Beneficially Number</u>	<u>Owned<sup>(1)</sup> Percent</u>
Yanlin Han		
Chief Executive Officer and Director Zhanguo Weng	31,651,403 <sup>(2)</sup>	50.3%
Director Xuemei Liu	9,200,401 <sup>(3)</sup>	14.6% 7.4%
Director Alexander Wick,	4,650,200 <sup>(4)</sup>	
Director Yiu Kwong Sun,	1,300,000 <sup>(5)</sup>	2.1%
Director Peter Mak,	1,100,000 <sup>(6)</sup>	1.7%
Director Heinz Frey,	200,000 <sup>(7)</sup>	0.3%
Director Jin Li,	200,000 <sup>(7)</sup>	0.3%
Director Maggie Deng	200,000 <sup>(7)</sup>	0.3%
Chief Operating Officer Garry Wong	400,000 <sup>(7)</sup>	0.6%
Chief Financial Officer	420,000 <sup>(7)</sup>	0.7%
All directors and executive officers as a group (10 persons)	49,322,004 <sup>(8)</sup>	78.4%

(1)

Except as otherwise indicated, we believe that the beneficial owners of the common stock listed above, based on information furnished by such owners or publicly available, have sole investment and voting power with respect to such shares, subject to community property laws where applicable. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock subject to options or warrants currently exercisable, or exercisable within sixty days, are deemed outstanding for purposes of computing the percentage ownership of the person holding such option or warrants, but are not deemed outstanding for purposes of computing the percentage ownership of any other person.

(2)

Includes options to purchase 500,000 shares.

(3)

Includes options to purchase 300,000 shares.

(4)

Includes options to purchase 400,000 shares.

(5)

Includes options to purchase 1,000,000 shares.

(6)

Includes options to purchase 400,000 shares. Also includes 600,000 shares of common stock owned by Yukon Health Enterprise for which Mr. Sun serves as director and officer.

(7)

Represents options exercisable within sixty days.

(8)

Includes options to acquire 4,020,000 shares of common stock.

### **Equity Compensation Plan Information**

Our shareholders approved a share option plan at our Annual Meeting held on December 18, 2001, authorizing 4,500,000 shares for issuance under the plan. At our Annual Meeting held on August 12, 2005, our shareholders approved another share option plan authorizing the issuance of a further 15,000,000 shares. The following table provides aggregate information as of December 31, 2006 with respect to all compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Plan Category	A	B	C
	Number of securities to be issued upon exercise of outstanding options, and warrants	Weighted-average exercise price of outstanding options, and warrants	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column A)
Equity compensation plans approved by security holders	5,312,500	\$0.91	14,187,500
Equity compensation plans not approved by security holders	0	-	0
Total	5,312,500	\$0.91	14,187,500

**ITEM 12.**

**CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE**

During the past two years, we have been a party to transactions involving certain of our directors or executive officers. See also Notes 11, 14(A) and 18 to our financial statements.

In January 2006, the Company disposed of the cell line, and all applicable obligations relating, thereto, being developed for the Company to enter the European market. The cell line was sold to AS Biotech AG, a Swiss company controlled by Dr. Alexander Wick, a Director of the Company who was also the President of the Company prior to the transaction. The cell line had a carrying value of \$0 at the time of the transaction and was sold for \$1 million with the assumption of all obligations under the agreement.

On June 29, 2006, the Company signed an agreement with an arm-length third party to sell part of the Pharma division, including all the formulation production facilities located in the Economic Development Zone in Datong, China, 258 drug approvals from the Chinese SFDA, 900 employees and the whole direct sales team to hospitals for the formulation business and related inventories, account receivables and account payables. The total selling price for the assets is \$13.32 million. The transaction was completed on July 1, 2006. In addition, the Company also signed a separate agreement, with an amendment on July 28, 2006, to deliver international registration documentation and services on a related product to this arm-length third party. This documentation and services agreement is valued at \$1.5 million and was completed in September, 2006. Subsequent to the transaction, Mr. Weng, a Director of the Company became a director of this party. During 2006, the Company has supplied some raw materials to this party and has used this party as a contract manufacturer for some of its Pharma division products.

Director Independence

Dr. Yiu Kwong Sun, Ms Xuemei Liu, Mr. Peter Mak, Mr. Henry Frey and Mr. Jin Li are deemed to be independent directors within the meaning of Section 407 (a)1.ii., Inter-dealer quotation system.

**ITEM 13.**

**EXHIBITS**

(a)

Exhibits

<u>Exhibit Number</u>	<u>Name</u>
2.1 <sup>(a)</sup>	Share Exchange Agreement with First Geneva Investments
3.1 <sup>(a)</sup>	Certificate of Incorporation and Amendments
	a. Certificate of Incorporation
	b. Certificate of Amendment, dated June 19, 1997
	c. Certificate of Amendment of Articles of Incorporation, dated September 21, 1998
3.2	Amended and Restated Bylaws
10.1 <sup>(a)</sup>	Sino-Foreign Co-operative Company Contract
10.2 <sup>(a)</sup>	Sino-Foreign Joint Venture Contract Between The Nanjing Medical Group Company Limited and Allwin Newtech Ltd.
10.3 <sup>(b)</sup>	Consulting Agreement with E. Pernet Portfolio Management dated June 15, 1999
10.4 <sup>(b)</sup>	Amendment to Sino-Foreign Co-operative Company Contract
10.5 <sup>(c)</sup>	Contract to lease 25 acres of land in Yanjiao, China
10.6 <sup>(c)</sup>	Sample Employment Agreement for technicians/employees
10.7 <sup>(d)</sup>	Marketing and License Agreement Between Allwin Biotrade and Fargin S.A.
10.8 <sup>(d)</sup>	Marketing and License Agreement Between Allwin Biotrade and Duopharma (Malaysia) SDN.BHD
10.9 <sup>(d)</sup>	Marketing and License Agreement Between Allwin Biotrade and Yoo & Yoo Biotech Co. Ltd.
10.10 <sup>(d)</sup>	Acquisition Agreement Among Dragon Pharmaceuticals Inc., Alphatech Bioengineering Limited, Longbin Liu and Philip Yuen
10.11 <sup>(e)</sup>	a.
	Sino Foreign Joint Venture Contract Between The Nanjing Medical Group Company Limited and Allwin Newtech Ltd.;
	b.

Amendment dated November 24, 2000;

c.

Amendment dated December 16, 2000; and

d.

Confirmation letter of control from The Nanjing Medical Group Company Limited to Allwin Newtech dated December 16, 2000

10.12<sup>(f)</sup> Joint research project with the Company and Shenzhen Kelong Chuang Jian Enterprise Co.

10.13<sup>(f)</sup> Patent Development Agreement with Dr. Longbin Liu and Novagen

<u>Exhibit Number</u>	<u>Name</u>
10.14 <sup>(f)</sup>	Project Development Agreement with Dr. Liu
10.15 <sup>(g)</sup>	2001 Stock Option Plan
10.16 <sup>(h)</sup>	Waivers of Certain Conditions to the Shares Purchase Agreement
10.17 <sup>(h)</sup>	Escrow Agreement among Dragon Pharmaceutical, Oriental Wave Holding Limited, Yanlin Han, Zhanguo Weng and Xuemei Liu.
10.18 <sup>(i)</sup>	Collaboration Agreement Among Transworld Pharmaceuticals Corporation Inc. and Toray Trading Corp. and Dragon Pharmaceutical Inc.
10.19 <sup>(i)</sup>	Agent Agreement Among Allwin Biotrade, Inc., Jiangsu Wuzhong Industry Co. Ltd. and Jiangsu Wuzhong Industry Co. Ltd. Suzhuo Zhang Kai Bio-Pharmaceuticals Plant
10.20 <sup>(i)</sup>	Development and Manufacturing Agreement Between Dragon Pharmaceutical Inc. and Polymun Scientific Immunbiologische Forschung GmbH
10.21 <sup>(i)</sup>	Agreement for Advance and Long Term Supply of Products between Aurobindo (Datong) Bio-Pharma Co. Ltd. and Shanxi Weiqida Pharmaceutical Co. Ltd.
10.22 <sup>(i)</sup>	Technology Transfer Agreement between Shanxi Weiqida Pharmaceutical Co., Ltd. and Alpha Process Trust Reg.
10.23 <sup>(i)</sup>	Manufacturing Agreement for Dry-freeze Levofloxacin Injectable by and between Shanxi Weiqida Pharmaceutical Co. and Shanxi Pude Pharmaceutical Co. Ltd.
10.24 <sup>(i)</sup>	Technology Transfer Agreement between Shanxi Weiqida Pharmaceutical Co., Ltd. and Alpha Process Trust Reg.
10.25 <sup>(k)</sup>	2005 Stock Option Plan
10.26	Assignment and Assumption Agreement among the Company, Polymun Scientific Immunbiological Forschung EmGH and AS Biotech AG.
21	Subsidiaries of the Registrant are:  Allwin Newtech Ltd., a British Virgin Island corporation;  Sanhe Kailong Bio-pharmaceutical Co. Ltd., a Chinese  Limited Liability Corporation;  Allwin Biotrade, Inc., British Virgin Island corporation;  Dragon Pharmaceuticals (Canada) Ltd, a British Columbia corporation;  Nanjing Huaxin Bio-Pharmaceutical Co., Ltd., a Chinese corporation;  Oriental Wave Holding, Ltd., a British Virgin Island corporation;  Shanxi Weiqida Pharmaceutical Ltd., a Chinese Corporation; and  Weixiang Bio-pharmaceutical Co., Ltd., a Chinese Corporation.
23.1	Consent of Ernst & Young LLP., Chartered Accountants
31.1	



	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
32	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act
99.1 (i)	Code of Ethics

---

(a)

Previously filed with Dragon's initial registration statement on Form 10-SB, filed with the SEC on November 4, 1999.

(b)

Previously filed with Dragon's initial registration statement on Form SB-2, filed with the SEC on May 15, 2000.

(c)

Previously filed with Dragon's amendment no. 1 to registration statement on Form SB-2 filed with the SEC on August 3, 2000.

(d)

Previously filed with Dragon's amendment no. 3 to registration statement on Form SB-2 filed with the SEC on October 20, 2000.

(e)

Previously filed with Dragon's amendment no. 5 to registration statement on Form SB-2 filed with the SEC on December 26, 2000.

(f)

Previously filed with Dragon's Form 10-K filed with the SEC on April 1, 2002.

(g)

Incorporated by reference to Dragon's proxy statement for the Annual Meeting held on December 17, 2001.

(h)

Incorporated by reference to Form 8-K filed on January 18, 2005

(i)

Incorporated by reference to Form 8-K filed on March 2, 2005, portions of which have been omitted for confidential treatment.

(j)

Incorporated by reference to Form 10-KSB for the year ended December 31, 2004 filed on April 23, 2004.

(j)

Incorporated by reference to the Company's proxy statement for 2005.

(b)

Reports on Form 8-K:

(1)

Form 8-K filed on November 22, 2005 announcing our financial results for the third quarter ended September 30, 2005.

(2)

Form 8-K filed October 5, 2005 announcing the appointment of directors.

(3)

Form 8-K filed on September 30, 2005 announcing the completion of the Acquisition of Oriental Wave Holding Limited and filing the financial statements of Oriental Wave Holding Limited for the year ended December 31, 2004, and pro-forma financial statements related thereto.

**ITEM 14.**

**ACCOUNTING FEES AND SERVICES.**

For the year ended December 31, 2006, Ernst & Young LLP was engaged by us to provide both audit and non-audit services. For the year ended December 31, 2005, Ernst & Young LLP was engaged by us to provide audit services. The following fees were paid for services provided by Ernst & Young LLP.

**Audit Fees.** The aggregate fees paid for the annual audit of financial statements included in our Annual Report for the year ended December 31, 2006 and 2005 and the review of our quarterly reports for such years, amounted to approximately \$410,000 and \$395,000, respectively.

**Audit Related Fees.** For the years ended December 31, 2006 and 2005 we paid \$Nil and \$Nil to Ernst & Young for other audit related fees.

**Tax Fees.** For the year ended December 31, 2006 and 2005, we paid \$Nil and \$Nil to Ernst & Young for tax fees.

**All Other Fees.** For the years ended December 31, 2006 and 2005, we paid \$7,051 and \$Nil to Ernst & Young for any non-audit services.

The above-mentioned fees are set forth as follows in tabular form:

	2006	2005
Audit Fees	\$410,000	\$395,000
Audit Related Fees	-0-	-0-
Tax Fees	-0-	-0-
All Other Fees	\$7,051	-0-

Audit Committee Approval of Audit and Non-Audit Services of Independent Accountants

The Audit Committee approves all audit and non-audit services provided by the independent auditors. These services may include audit services, audit-related services, tax services and other services. The independent accountants and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent accountants, and the fees for the services performed to date. No non-audit services were provided by our independent accountants in 2005.

SIGNATURE

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March ,2007

Dragon Pharmaceutical Inc.,  
a Florida Corporation

*/s/ Yanlin Han*  
Yanlin Han, Chief Executive Officer  
(Principal Executive Officer)

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures

Date

*/s/ Yanlin Han*

Mr. Yanlin Han, Chairman of the Board

March \_\_\_\_\_ , 2007

*/s/ Zhanguo Weng*

Mr. Zhanguo Weng, Director

March \_\_\_\_\_ , 2007

/s/ Dr. Yiu Kwong Sun

Dr. Yiu Kwong Sun, Director

March \_\_\_\_\_ , 2007

/s/ Dr. Alexander Wick

Dr. Alexander Wick, Director

March \_\_\_\_\_ , 2007

/s/ Xuemei Liu

Ms. Xuemei Liu, Director

March \_\_\_\_\_ , 2007

/s/ Peter Mak

Mr. Peter Mak, Director

March \_\_\_\_\_ , 2007

/s/ Heinz Frey

Mr. Heinz Frey, Director

March \_\_\_\_\_ , 2007

/s/ Jin Li

Mr. Jin Li, Director

March \_\_\_\_\_ , 2007

/s/ Garry Wong

Garry Wong, Chief Financial Officer

March \_\_\_\_\_ , 2007

(Principal Financial and Accounting Officer)





CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-55794) pertaining to Stock Options Granted to Directors, Technical Advisors, and Employees under Stock Option Agreements of our report dated March 27, 2007, with respect to the consolidated financial statements of Dragon Pharmaceutical Inc. included in the Annual Report (Form 10-KSB) for the year ended December 31, 2006.

Vancouver, Canada

March 30, 2007

/s/ Ernst & Young LLP

Chartered Accountants



**Section 302 Certification of Principal Executive Officer**

I, Yanlin Han, certify that:

1. I have reviewed this annual report on Form 10-KSB of Dragon Pharmaceutical Inc.;
  
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
  
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
  - b) Omitted
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and
  
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: : March 30, 2007

/s/ Yanlin Han

Yanlin Han

Chief Executive Officer

**Section 302 Certification of Principal Financial Officer**

I, Garry Wong, certify that:

1. I have reviewed this annual report on Form 10-KSB of Dragon Pharmaceutical Inc.;
  
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
  
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
  - b) Omitted
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and
  
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: : March 30, 2007

/s/ Garry Wong

Garry Wong,

Chief Financial Officer

CERTIFICATION  
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  
(SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF  
TITLE 18, UNITED STATES CODE)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States Code), each of the undersigned officers of Dragon Pharmaceutical Inc., a Florida corporation (the "Company"), does hereby certify with respect to the Annual Report of the Company on Form 10-KSB for the year ended December 31, 2006 as filed with the Securities and Exchange Commission (the "Form 10-KSB") that, to the best of their knowledge:

- (1) the Form 10-KSB fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Form 10-KSB fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: : March 30, 2007

/s/ Yanlin Han  
Yanlin Han  
Chief Executive Officer

Dated: : March 30, 2007

/s/ Garry Wong  
Garry Wong  
Chief Financial Officer

